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Abstract 
Background: Patients with ovarian cancer often present at advanced stage and, following initial treatment success, 
develop recurrent drug‑resistant disease. PARP inhibitors (PARPi) are yielding unprecedented survival benefits for 
women with BRCA‑deficient disease. However, options remain limited for disease that is platinum‑resistant and/or has 
inherent or acquired PARPi‑resistance. PARG, the PAR glycohydrolase that counterbalances PARP activity, is an emerg‑
ing target with potential to selectively kill tumour cells harbouring oncogene‑induced DNA replication and metabolic 
vulnerabilities. Clinical development of PARG inhibitors (PARGi) will however require predictive biomarkers, in turn 
requiring an understanding of their mode of action. Furthermore, differential sensitivity to PARPi is key for expanding 
treatment options available for patients.
Methods: A panel of 10 ovarian cancer cell lines and a living biobank of patient‑derived ovarian cancer models 
(OCMs) were screened for PARGi‑sensitivity using short‑ and long‑term growth assays. PARGi‑sensitivity was character‑
ized using established markers for DNA replication stress, namely replication fibre asymmetry, RPA foci, KAP1 and Chk1 
phosphorylation, and pan‑nuclear γH2AX, indicating DNA replication catastrophe. Finally, gene expression in sensitive 
and resistant cells was also examined using NanoString or RNAseq.
Results: PARGi sensitivity was identified in both ovarian cancer cell lines and patient‑derived OCMs, with sensitivity 
accompanied by markers of persistent replication stress, and a pre‑mitotic cell cycle block. Moreover, DNA replica‑
tion genes are down‑regulated in PARGi‑sensitive cell lines consistent with an inherent DNA replication vulnerability. 
However, DNA replication gene expression did not predict PARGi‑sensitivity in OCMs. The subset of patient‑derived 
OCMs that are sensitive to single‑agent PARG inhibition, includes models that are PARPi‑ and/or platinum‑resistant, 
indicating that PARG inhibitors may represent an alternative treatment strategy for women with otherwise limited 
therapeutic options.
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Background
Ovarian cancer is a leading cause of gynaecological 
cancer-related death, accounting for more than 200,000 
deaths globally in 2020 [1, 2]. The most prevalent sub-
type, high-grade serous ovarian cancer (HGSOC), 
accounts for approximately 70% of cases and is frequently 
lethal because it is highly aggressive and presents at an 
advanced stage where cure is unlikely [3]. Treatment 
options are limited, but typically include cytoreductive 
surgery plus paclitaxel/platinum chemotherapy, with 
maintenance therapy used in specific subgroups [4, 5]. 
While many patients initially respond well, most develop 
recurrent disease, yielding 10-year survival rates of only 
~ 35% [6–9].
HGSOC is characterised by ubiquitous TP53 muta-
tions, and extensive copy number variation (CNV) [10, 
11], implying chromosome instability [12], and indeed, 
HGSOC is one of the most chromosomally unstable can-
cers [6, 11, 13]. Approximately 50% have homologous 
recombination (HR) deficiency (HRD), which in ~ 20% of 
cases is due to alteration of BRCA1 or BRCA2 [14]. While 
targeted therapies have led to personalised treatments 
across many cancers, this therapeutic strategy is limited 
in HGSOC due to the paucity of actionable driver muta-
tions. Other therapeutic strategies are therefore required 
and indeed, HRD opened up an alternative: synthetic 
lethality. This approach was pioneered by the ability of 
poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) 
to selectively kill BRCA -mutant cells [15, 16], and these 
drugs are now yielding major benefits for patients with 
HRD tumours [17–20]. However, this leaves ~ 50% of 
cases that are HR-proficient (HRP) and therefore unlikely 
to benefit from a PARPi. Furthermore, the majority 
of HRD tumours will eventually acquire PARPi resist-
ance with treatment [21]. Thus, alternative strategies are 
required to improve outcomes for women with inher-
ent and acquired resistance to both PARP inhibition and 
platinum-based chemotherapy.
To develop novel therapeutic strategies, attention is 
focussing on targeting poly(ADP-ribose) (PAR) glyco-
hydrolase (PARG), the enzyme that counterbalances 
PARP1/2 activity [22–27]. Thus far, we have character-
ised PARG inhibitor PDD00017273, hereafter PARGi, 
a quinazolinedione that inhibits PARG with an in  vitro 
 IC50 of 26 nM [28]. Upon analysing a panel of six ovar-
ian cancer cell lines in response to PARGi and the PARP 
inhibitor Olaparib, hereafter PARPi, we discovered that 
OVSAHO, COV318, COV362 and CAOV3 proliferated 
in both inhibitors, while Kuramochi and OVCAR3 dis-
played differential sensitivities; Kuramochi proliferation 
was suppressed by PARGi, while OVCAR3 proliferation 
was suppressed by PARPi [26]. Sensitivity of Kuramo-
chi to PARGi was accompanied by pan-nuclear γH2AX 
staining, which is indicative of replication catastrophe 
[29], and a synthetic lethal siRNA screen identified sev-
eral DNA replication genes, including TIMELESS, that 
when inhibited sensitised OVCAR3 to PARGi. Further-
more, PARGi induced replication fork asymmetry in 
Kuramochi but not OVCAR3, suggesting that Kuramochi 
cells have an underlying DNA replication vulnerability 
that causes frequent fork stalling, and are thus more reli-
ant on PARG to re-start stalled forks, possibly by revers-
ing PARP-mediated inhibition of RECQ1 [26].
The notion that DNA replication vulnerabilities might 
confer PARGi sensitivity led to the identification of 
additional PARGi-sensitive cell lines; interrogation of 
Cancer Cell Line Encyclopedia (CCLE) data identified 
several ovarian cancer cell lines with down-regulated 
DNA replication genes, namely HS571T, RMG1, OV56, 
OVMANA and OVISE, as well as Kuramochi [26]. While 
HS571T is no longer available for research purposes, 
we obtained RMG1, OV56, OVMANA and OVISE, and 
showed that RMG1 and OVMANA are PARGi-sensi-
tive. This raised the possibility that a DNA “replication 
stress” gene expression signature might have potential as 
a predictive biomarker of PARGi sensitivity. Importantly, 
like Kuramochi, RMG1 showed differential sensitivity 
to PARGi and PARPi. However, while OVMANA were 
more sensitive to PARGi than PARPi, the distinction was 
less clear-cut.
These observations indicate that PARG inhibitors may 
open up new opportunities to treat ovarian cancers. 
However, a number of questions remained unanswered. 
Firstly, is the PARGi sensitivity exhibited by different cell 
lines mediated via the same mechanism? While PARGi 
prevents proliferation of RMG1 and OVMANA, whether 
Conclusions: We discover that a subset of ovarian cancers are intrinsically sensitive to pharmacological PARG block‑
ade, including drug‑resistant disease, underpinned by a common mechanism of replication catastrophe. We explore 
the use of a transcript‑based biomarker, and provide insight into the design of future clinical trials of PARGi in patients 
with ovarian cancer. However, our results highlight the complexity of developing a predictive biomarker for PARGi 
sensitivity.
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this was due to the replication catastrophe phenom-
enon exhibited by Kuramochi cells was not established. 
Secondly, does PARGi sensitivity correlate with down-
regulated DNA replication genes? While the CCLE data 
indicated that DNA replication genes are down-regulated 
in OV56 and OVISE, their PARGi sensitivity was unclear 
[26]. If resistant, the utility of a DNA “replication stress” 
gene expression signature as a predictive biomarker of 
PARGi sensitivity is uncertain. To address these two 
questions, we set out to perform a detailed analysis 
of a panel of ovarian cancer cell lines to determine (a) 
whether PARGi sensitivity is via a common replication 
catastrophe mechanism, and (b) whether PARGi sensi-
tivity does indeed correlate with the relative expression 
levels of DNA replication genes. Moreover, to assess the 
translational opportunity of PARGi, we screened a panel 
of patient-derived ovarian cancer models (OCMs) [13] 
to determine whether any were PARGi sensitive and if 
this sensitivity is via a replication stress mechanism that 




PDD00017273 (PARGi; Tocris Bioscience), 
PDD00031704 [PARGi-Me [28]], olaparib (PARPi; 
AZD2281, KU0059436; Selleckchem), niraparib tosylate 
(MK-4827, Zejula; Selleckchem) and paclitaxel (Sigma-
Aldrich) were dissolved in DMSO. Cisplatin (Sigma-
Aldrich) was dissolved in 0.9% NaCl. Hydroxyurea 
(Sigma-Aldrich) was dissolved in  ddH2O. BrdU and IdU 
(Sigma-Aldrich) were dissolved in DMSO and culture 
media, respectively.
Established cell lines
The ovarian cancer cell lines OVCAR3 (ATCC), Kuramo-
chi, OVMANA, OVSAHO, OVISE (JCRB Cell Bank) 
were grown in RPMI; COV362, COV318 (Sigma-Aldrich) 
and CAOV3 (ATCC) were grown in DMEM; RMG1 
(JCRB Cell Bank) was grown in Ham’s F12 (Sigma-
Aldrich); all supplemented with 10% foetal bovine serum 
(FBS; Life Science Group), 100 U/ml streptomycin, 100 U/
ml penicillin (Sigma-Aldrich), 2 mM glutamine (Sigma-
Aldrich) and maintained at 37 °C in a humidified 5% 
 CO2 atmosphere. OV56 (Sigma-Aldrich) was grown in 
DMEM/F12 with FBS reduced to 5% and supplemented 
with 10 μg/ml insulin, 0.5 μg/ml hydrocortisone, 100 U/
ml streptomycin, 100 U/ml penicillin, 2 mM glutamine 
and maintained at 37 °C in a humidified 5%  CO2 atmos-
phere. All ovarian cancer cell lines were authenticated by 
the Molecular Biology Core Facility at the CRUK Man-
chester Institute using Promega Powerplex 21 System, 
and underwent periodic testing for mycoplasma.
Ex vivo ovarian cancer models (OCMs)
Research samples were obtained with informed patient 
consent from the Manchester Cancer Research Centre 
(MCRC) Biobank. The MCRC Biobank is licensed by 
the Human Tissue Authority (license number: 30004) 
and is ethically approved as a research tissue bank by the 
South Manchester Research Ethics Committee (Ref: 18/
NW/0092). The role of the MCRC Biobank is to distrib-
ute samples and does not endorse studies performed or 
the interpretation of results. For more information, see 
https:// www. mcrc. manch ester. ac. uk/ resea rch/ mcrc- 
bioba nk. Ex  vivo ovarian cancer models (OCMs) were 
expanded from ascites samples from 32 patients, of 
which seven were published previously [13]. All patients 
were initially diagnosed with HGSOC, however four 
were re-classified to: cytological diagnosis of ‘suspicion 
of adenocarcinoma arising from the gynaecological tract’ 
(patients 87 and 195), moderately differentiated (inter-
mediate grade/grade 2) serous adenocarcinoma (patient 
152), and low-grade serous ovarian cancer (patient 64) 
[30]. The age at diagnosis ranged from 44 to 84 years, the 
mean age at diagnosis was 62.8 years. Five samples were 
chemonaïve (patients 87, 110, 99, 195 and 231).
Ovarian cancer and stromal cells from patients were 
cultured as previously described [13]. In brief, OCMI 
media [31] was used with a 50:50 mix of Nutrient Mix-
ture Ham’s F12 and Medium 199 (Life Technologies) 
supplemented with 5% FBS or 5% Hyclone FBS (Cytiva), 
2 mM glutamine, 100 U/ml penicillin, 100 U/ml strepto-
mycin, 10 mM HEPES at pH 7.4, 20 μg/ml insulin, 0.01 μg/
ml EGF, 0.5 μg/ml hydrocortisone, 10 μg/ml transferrin, 
0.2 pg/ml Triiodothyronine, 5 μg/ml o-phosphorylethan-
olamine, 8 ng/ml selenious acid, 0.5 ng/ml 17β-oestradiol, 
5 μg/ml all trans retinoic acid, 1.75 μg/ml hypoxanthine, 
0.05 μg/ml lipoic acid, 0.05 μg/ml cholesterol, 0.012 μg/
ml ascorbic acid, 0.003 μg/ml α-tocopherol phosphate, 
0.025 μg/ml calciferol, 3.5 μg/ml choline chloride, 0.33 μg/
ml folic acid, 0.35 μg/ml vitamin  B12, 0.08 μg/ml thiamine 
HCL, 4.5 μg/ml i-inositol, 0.075 μg/ml uracil, 0.125 μg/ml 
ribose, 0.0125 μg/ml para-aminobenzoic acid, 1.25 mg/
ml BSA, 0.085 μg/ml xanthine and 25 ng/ml cholera 
toxin (all from Sigma-Aldrich). To establish OCMs 
500–1000 mL of ascitic fluid was centrifuged (500×g 
for 10 min at 4 °C) and cell pellets pooled in HBSS (Life 
Technologies). Red blood cells were removed using a red 
blood cell lysis buffer (Miltenyi Biotec) as per the manu-
facturer’s instructions. Tumour cells were seeded into 
Primaria flasks containing OCMI. Cultures were incu-
bated for 2–4 days at 37 °C in a humidified 5%  CO2 and 
5%  O2 atmosphere. Media was replaced every 3–4 days. 
Upon cell attachment, stromal cells were separated from 
the mixed sample using 0.05% trypsin-EDTA (Sigma-
Aldrich) and seeded in gelatin-coated flasks in OCMI 
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media containing 5% FBS (Life Science Group). Once 
tumour cells reached 95% confluency, cells were passaged 
using 0.25% Trypsin-EDTA, centrifuged in DMEM con-
taining 20% FBS and re-plated at a 1:2 ratio.
Colony formation assay
For established ovarian cancer cell lines, 1000 cells per 
well were seeded into 6-well plates  24 h prior to drug 
treatment. For OCMs, 2000 cells per well were seeded 
into either Primaria or collagen coated (50 μg/mL of 
BD collagen type I, rat tail, [BD Biosciences Discovery 
Labware] in 0.02 N Acetic Acid for 1 h prior to seeding) 
6-well plates 24 h prior to drug treatment. For OCM.165, 
tumour cells were seeded at 4000 cells per well 24 h prior 
to drug treatment. DMSO (control), PARGi, PARGi-Me 
or PARPi were added; cells were treated either continu-
ously or the drugs were washed out at the specific time 
points as indicated in the figures. Following colony for-
mation (range: 2–4 weeks for ovarian cancer cell lines; 
range: 2–12 weeks for OCMs), colonies were fixed in 1% 
formaldehyde for 10 min, stained with 0.05% (w/v) crys-
tal violet solution (Sigma-Aldrich) for 10 min and rinsed 
with  ddH2O. Plates were imaged using a ChemiDoc™ 
Touch Imaging System (BioRad), and analysed with an 
ImageJ ‘colony area’ plug-in [32].
Immunofluorescence
All cells were plated onto either 13 mm or 19 mm cov-
erslips 24 h prior to drug treatment. For RMG1 cells, 
coverslips were coated with 0.01% Poly-L-Lysine (Sigma-
Aldrich). For OCMs, coverslips were collagen coated 
(as above) prior to plating. OCMs were plated at 28,000 
cells per coverslips (on 19 mm coverslips) for 24 h prior 
to drug treatment. OCM.165 was plated at 112,000 cells 
per coverslip. All OCMs were plated for 48 h prior to 
immunofluorescence staining for markers of HGSOC, 
including: p53, Paired-box gene 8 (PAX8) and cytokera-
tin 7 (CK7). For immunofluorescence staining, cells 
were washed with PBS (× 2), fixed in 1% formaldehyde 
for 5 min, quenched with glycine for 5 min, washed in 
PBS-T (PBS plus 0.1% Triton X-100) and then incu-
bated with primary antibodies (rabbit anti-CK7, 1:1000, 
Abcam cat#ab68459 RRID: AB_1139824; mouse anti-p53 
[DO-1], 1:1000, Santa Cruz Biotechnology cat#sc-126 
RRID: AB_628082; rabbit anti-PAX8, 1:100, Abcam 
cat#ab53490 RRID: AB_2267905; mouse anti-PAR, 1:400, 
Merck Millipore cat#AM80 RRID: AB_2155072; mouse 
anti-γH2AX pS139, 1:2000, Merck Millipore cat#05–636 
RRID: AB_309864; rabbit anti-pKAP1, 1:500, Bethyl Lab-
oratories cat#A300-767A RRID: AB_669740; rabbit anti-
RPA70, 1:500, Abcam cat#ab79398 RRID: AB_1603759; 
rabbit anti-Rad51, 1:1000, Bio academia cat#70–001 
RRID: AB_2177110; sheep anti-CENP-F, 1:1000 [33] in 
PBS-T or 1% dried skimmed milk (Marvel), after 15 min 
blocking in 1% milk for PAR staining, for 1 h at room tem-
perature. Coverslips were then washed with PBS-T (× 3) 
and incubated with the appropriate fluorescent conju-
gate secondary antibodies (donkey anti-rabbit Cy2, 1:500, 
cat#711–225-152 RRID: AB_2340612; donkey anti-rabbit 
Cy3, 1:500, cat#711–165-152 RRID: AB_2307443; don-
key anti-mouse Cy2, 1:500, cat#715–225-150 RRID: 
AB_2340826; donkey anti-mouse Cy3, 1:500, cat#715–
165-150 RRID: AB_2340813; donkey anti-sheep Cy3, 
1:500, cat#713–165-147; RRID: AB_2315778; all Jackson 
ImmunoResearch Laboratories) for 30 min at room tem-
perature. Coverslips were then washed with PBS-T (× 3) 
and DNA was stained for 1 min with 1 μg/ml Hoechst 
33258 (Sigma-Aldrich) at room temperature. Coverslips 
were then washed with PBS-T (× 3) and mounted (90% 
glycerol, 20 mM Tris, pH 9.2) onto slides. Image acquisi-
tion used an Axioskop 2 (Zeiss) microscope fitted with 
a CoolSNAP HQ camera (Photometrics) using Meta-
Morph Software (Molecular Devices).
For high-throughput immunofluorescence, cells were 
processed as above in 96-well plates (PerkinElmer Cell 
Carrier) with two additional final washes in PBS. For 
RMG1, wells were coated with 0.01% Poly-L-Lysine. 
For OCMs, plates were collagen coated (as above) prior 
to plating. For ovarian cell lines, cells were seeded at 
2000–28,000 per well. For OCMs, cells were seeded at 
750–6000 cells per well. Images were acquired using 
Operetta® High Content Imaging System (PerkinElmer) 
and quantified using Columbus High Content Imag-
ing and Analysis Software (PerkinElmer). Mean fluores-
cence intensity or foci quantification within the nuclear 
area (demarcated using Hoechst stain) using Columbus 
‘spot finder’ tool, was quantified as a mean value per cell. 
These were also calculated for secondary antibody-only 
exposed cells (control). For final values, secondary anti-
body-only control mean values were subtracted from the 
stained cell mean values.
Lentiviral production and transduction
To produce the GFP-H2B cells, AAV293T cells (Agilent 
Technologies) were plated at 5 ×  104 cells per well in a 
24-well plate. Media was replenished 1 h before trans-
fection. Cells were transfected with pLVX-based lenti-
viral plasmids (Takara Bio), modified to express human 
histone H2B tagged at the N-terminus with GFP (pLVX-
myc-EmGFP-H2B) plus psPAX2 and pMD2.G (Addgene) 
using 16.6 mM  CaCl2 (Promega) in DMEM supple-
mented with 10% Hyclone FBS and incubated overnight. 
Virus was harvested 48 h after transfection, centrifuged 
and filtered (0.45 μm). Cells were seeded at 2–10 ×  105 
cells per well in a 12-well plate and diluted lentivirus and 
10 μg/ml polybrene (Sigma-Aldrich) added 48 h later. 
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The 12-well plates were centrifuged at 300×g for 2.5 h 
at 30 °C. 1 mL of culture media was added and the plates 
incubated overnight. Puromycin (Sigma Aldrich) (2 μg/
ml for OVMANA, 1 μg/ml for all other ovarian cancer 
cell lines and OCMs) was added 48 h after transduction.
Drug sensitivity assay and cell fate profiling
Ovarian cancer cell lines were seeded, at 500–8000 cells 
per well and OCMs at 750–6000 cells per well, into a 
96-well plate (Greiner Bio-One) 24 h prior to drug treat-
ment. For OCMs, 96-well plates were coated with col-
lagen (as above) prior to plating. To determine half 
maximal effective concentration  (EC50), cells express-
ing GFP-H2B were used and PARGi, PARGi-Me, PARPi, 
niraparib tosylate and cisplatin were serially diluted from 
100 μM–0.381 nM (19 concentrations in total). Pacli-
taxel was serially diluted from 10 μM–0.0381 nM (19 
concentrations in total). Following drug treatment, cells 
were imaged using an IncuCyte® ZOOM (Essen BioSci-
ence) equipped with a 20X objective and maintained at 
37 °C in a humidified 5%  CO2 atmosphere for ovarian cell 
lines or a humidified 5%  CO2 and 5%  O2 atmosphere for 
OCMs. Nine phase contrast and fluorescence images (for 
GFP-H2B expressing cells) were collected per well every 
4 or 6 h for 120 h to analyse cell proliferation. To deter-
mine cell fates, cells were treated with DMSO, PARGi or 
PARPi, and cells were imaged every 10 min for 120 h.
IncuCyte® ZOOM software was used in real-time to 
measure green object count in cells expressing GFP-H2B, 
as a proxy for cell proliferation. Green object count was 
used to generate dose-response curves in Prism (Graph-
Pad) from which  EC50 values were calculated. In highly 
resistant cells, in which  EC50 could not be determined 
accurately, the  EC50 assigned a value of 50 μM (i.e. half 
the maximum dose tested). To generate cell fate profiles, 
image sequences were exported in MPEG-4 format and 
analysed manually to time and annotate cell behaviours 
[34]. Prism 8 (GraphPad) was used for statistical analysis 
and presentation.
Immunoblotting
Ovarian cancer cells lines were treated with DMSO, 
PARGi or PARPi for 48 h prior to harvesting, or for 2 h 
with 2 mM Hydroxyurea as a positive control. OCMs 
were treated with DMSO, PARGi or PARPi for 96 h prior 
to harvesting, or exposed to 10 Gy of x-ray ionising radia-
tion (IR) using the Faxitron® (Hologic), 4 h prior to har-
vesting, as a positive control. Proteins were extracted, 
quantified by Bradford assay, then denatured by boiling 
in sample buffer (0.35 M Tris pH 6.8, 0.1 g/ml sodium 
dodecyl sulphate, 93 mg/ml dithiothreitol, 30% glycerol, 
50 μg/ml bromophenol blue). Proteins were resolved by 
SDS-PAGE and electroblotted onto Immobilon-Fl PVDF 
membrane (Millipore; LI-COR) or Immobilon - P Trans-
fer Membrane (Millipore). For LI-COR imaging, in place 
of a loading control REVERT total protein stain solution 
(LI-COR) was used for normalisation: membrane was 
incubated with REVERT solution for 5 min, followed by 
washing in 6.7% (v/v) glacial acetic acid in water, 30% 
(v/v) methanol in water. Before imaging on the Odys-
sey® CLx Imaging System (Li-COR), the membrane was 
washed with water. Following imaging, REVERT stain 
was removed using REVERT reversal solution (0.1 M 
NaOH, 30% v/v methanol in water). Membranes were 
then blocked using 5% dried skimmed milk or 5% BSA 
(for anti-pChk1) diluted in TBS-T (50 mM Tris pH 7.6, 
150 mM NaCl, 0.1% Tween-20).
Primary antibodies (mouse anti-Chk1, 1:500, Santa 
Cruz Biotechnology cat#sc-8408 RRID: AB_627657; rab-
bit anti-pChk1, 1:750, Cell Signalling cat#2348 RRID: 
AB_331212; mouse anti-PAR, 1:400, Merck Millipore 
cat#AM80 RRID: AB_2155072; mouse anti-p53 [DO-
1], 1:1000, Santa Cruz Biotechnology cat#sc-126 RRID: 
AB_628082; sheep anti-Bub3, 1:1000 [A. Holland and 
S.S. Taylor, unpublished data]; sheep anti-Tao1, 1:1000 
[35]) were diluted in 5% dried skimmed milk or 5% BSA 
(for pChk1) diluted in TBS-T. Membranes were washed 
in TBS-T (× 3 20 min) and incubated for at least 1 h 
with the appropriate secondary antibody. For LI-COR, 
fluorescently-conjugated secondary antibodies (IRDye® 
800CW donkey anti-rabbit, 1:5000, cat#925–32,213 
RRID: AB_2715510; IRDye® 680RD donkey anti-mouse, 
Cat#926–68,072 RRID: AB_10953628; both LI-COR) 
were diluted in 5% dried skimmed milk (Marvel) 0.2% 
Tween-20 + 0.01% SDS TBS.
For chemiluminescent detection, membranes were 
incubated with horseradish peroxidase-conjugated anti-
bodies (rabbit anti-sheep IgG (H + L), 1:2000, cat#61–
8620 RRID: AB_2533942; goat anti-mouse IgG (H + L), 
1:2000, cat#G21040 RRID: AB_2536527; Goat anti-rabbit 
IgG (H + L), 1:2000, cat#G21234 RRID: AB_2536527; all 
from Invitrogen) in 5% dried skimmed milk or 5% BSA 
(for pChk1 antibody) diluted in TBS-T. Membranes were 
washed TBS-T (× 3 20 min) before secondary horse-
radish peroxidase-conjugated antibodies were detected 
using EZ-ECL chemiluminescence reagent (Geneflow) 
or Luminata Forte Western HRP Substrate (Merck Mil-
lipore) and imaged on ChemiDoc Touch Imaging System 
(BioRad). For LI-COR, membranes were rinsed with TBS 
and imaged on Odyssey® CLx Imaging System (LI-COR).
Functional Rad51 assay
OCM.109, OCM.246, OVCAR3 and Kuramochi cells 
were seeded overnight onto collagen coated (see above) 
19 mm coverslips at a cell density of 112,000, 56,000, 
36,000 and 36,000 cells per coverslip, respectively. The 
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following day, cells were exposed to 2 Gy of X-ray IR and 
1 μM of PARPi or DMSO control for 24 h. Cells were 
stained for CENPF and Rad51 by the previously stated 
immunofluorescence protocol. To determine the HR sta-
tus, the number of CENPF-positive nuclei containing ≥5 
Rad51 foci (CENPF+Rad51+) was calculated for 10 sep-
arate fields of view, using the Axioskop 2 (Zeiss) micro-
scope, at 40x magnification. A < 2-fold rise in the ratio of 
Rad51 + CENPF+ cells/CENPF+ cells following IR plus 
PARPi treatment versus control, was reported as HRD.
DNA fibre assay
Sample preparation
Sub-confluent cells were incubated in the presence of 
DMSO or PARGi for 48 h, then pulsed with BrdU at 5 μM 
plus DMSO or PARGi for 20 min. This was followed by 3 
washes with warm PBS, pulsing with 200 μM IdU (Sigma-
Aldrich) plus DMSO or PARGi for a further 20 min, then 
washing twice with ice-cold PBS. Following trypsini-
sation using 0.05% Trypsin-EDTA (Gibco), cells were 
diluted in ice-cold PBS to give a final concentration of 
1–5 ×  105 cells/ml and kept on ice.
Slide preparation
The cell suspension (2 μl) was then dropped onto micro-
scope slides and dried at room temperature for 5–10 min 
before mixing with 7 μl of spreading buffer (200 mM Tris-
HCl pH 7.5, 50 mM EDTA, and 0.5% SDS), and incubat-
ing for a further 5 min. Slides were tilted approximately 
5–10° so that the cell suspension runs across the length 
of the slide. Slides were air dried and fixed in methanol/
acetic acid (3:1) for 10 min, air dried and stored at 4 °C.
Immunostaining
Prior to immunostaining, slides were washed twice with 
 ddH2O for 5 min, 1 × 2.5 M HCl, denatured with 2.5 M 
HCl for 1 h, rinsed twice with PBS and then washed with 
blocking solution (PBS with 1% BSA and 0.1% Tween-
20) twice for 5 min and then for 1 h. For immuno-label-
ling all antibodies were dissolved in blocking solution. 
Slides were then incubated with a rat anti-BrdU anti-
body (BU1/75 [ICR1], 1:500, Abcam cat# 6326; RRID: 
AB_305426) to detect BrdU for 1 h under humidified 
conditions, rinsed with PBS (× 3), fixed for 10 min with 
1% formaldehyde, rinsed with PBS (× 3), and quenched 
with glycine. Slides were then rinsed with PBS (× 3) fol-
lowed by overnight, 4 °C incubation with mouse anti-
BrdU (B44, 1:100, BD Biosciences cat#347580; RRID: 
AB_400326) to detect IdU. Slides were then washed twice 
with PBS, 3 times for 5 min in blocking solution, followed 
by incubation in the appropriate fluorescently-conju-
gated secondary antibodies diluted in blocking solution 
(1:500; donkey anti-rat Cy3 cat#712–165-153 RRID: 
AB_2340667; donkey anti-mouse Cy2 cat#715–225-150 
RRID: AB_2340826; all Jackson ImmunoResearch Labo-
ratories) for 1.5 h. Post-incubation, slides were washed 2 
x PBS, 3 × 5 min with blocking solution and 2 x PBS. All 
slides were mounted to coverslips using PBS/Glycerol 
(1:1).
Imaging and quantitation
Images were acquired using an Axioskop 2 (Zeiss) micro-
scope fitted with a CoolSNAP HQ camera (Photomet-
rics) and 2–5 slides analysed per condition. Fibre lengths 
were quantified using ImageJ software (NIH).
Genotyping of OCMs
TP53 genotyping by sanger sequencing
RNA was extracted using RNeasy Plus Mini kit (Qiagen) 
as per manufacturer’s instructions. TP53 complemen-
tary DNA was generated by RT-PCR using Superscript 
III One Step RT-PCR Platinum Taq HiFi (Thermofisher). 
PCR products were cloned into a pBluescript SK-vector 
and transformed into XL1-Blue competent cells. Plas-
mid DNA was extracted using QIAprep Spin Miniprep 
Kit (Qiagen) and sequenced using the following primers 
(5′-CAC CAG CAG CTC CTA CAC CG-3′, 5′-ATG AGC 
GCT GCT CAG ATA GCG-3′, 5′-CGG CTC ATA GGG 
CAC CAC C-3′, 5′- TCT TCT TTG GCT GGG GAG 
AGG-3′). Tumour sequences were aligned using Seqman 
Pro (DNASTAR).
BRCA1/2 genotyping by next generation sequencing (NGS)
DNA from OCMs was extracted using the cobas® DNA 
Sample Preparation Kit (Roche). Library enrichment 
used the GeneRead DNAseq BRCA1 & BRCA2 version 
2 kit (Qiagen). 20 ng DNA was amplified in 4 multiplex 
primer pools. Following PCR-based target enrichment, 
library preparation and purification followed a custom 
protocol using AMPure XP beads (Beckman Coulter) 
for size selection and TruSeq PCR-Free indexes and rea-
gents for indexing (Illumina). The DNA library was then 
paired-end sequenced on an MiSeq (Illumina) with v2 
chemistry (2 × 150 cycles). Bioinformatic analysis used an 
in-house pipeline, which has been validated to detect low 
level mosaic calls down to a variant allele fraction of 4% 
and used a software consensus between VarScan v2.3.6 
and DREEP v0.7. Large indel events were assessed using 
Pindel v0.2.4.t. The NGS assay was able to detect single-
nucleotide variants and duplications, deletions and inser-
tions ≤40 base pairs in length, across the whole coding 
sequence of BRCA1 and BRCA2 +/− 15 base pairs 
beyond each exon-intron junction. The target read depth 
across all coding exons was a minimum of 350X. All vari-
ant calls identified following bioinformatics analysis were 
independently reviewed within a genome browser. At a 
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variant allele frequency ≥ 4% had a call sensitivity > 95% 
and specificity > 99% after a manual review.
BRCA1/2 genotyping by multiplex ligation probe 
amplification (MLPA)
Testing for genomic rearrangements/copy number vari-
ation in BRCA1/2 was performed by MLPA using the 
MRC Holland probe kits P002-D1 (BRCA1) and P045-C1 
(BRCA2). Amplified ligation products were subject to 
fragment analysis using an ABI 3130xl Genetic Analyser 
and size called using GeneMapper v2.0 (Applied Biosys-
tems). Copy number status calling was performed using 
data exported from GeneMapper using custom-devel-
oped MLPA spreadsheets that report relative dosage 
quotient for each probe compared with reference control 
samples. All MLPA analysis assays were performed in 
duplicate for confirmation of results.
scWGS karyotyping
As described previously, [13], single G1 nuclei were iso-
lated by cell sorting then processed for sequencing using 
a Bravo Automated Liquid Handling Platform (Agilent 
Technologies) [36, 37]. Samples were sequenced on an 
Illumina NextSeq 450 at ERIBA (Illumina). Unprocessed 
sequencing reads were demultiplexed using library-
specific barcodes and converted into fastq format using 
standard Illumina software (bcl2fastq version 1.8.4). 
Demultiplexed reads were aligned to human reference 
genome GRCh38 using Bowtie2 (version 2.2.4). Dupli-
cate reads were marked and removed using BamUtil (ver-
sion 1.0.3.). Aligned sequencing reads were analysed and 
curated using AneuFinder (version 1.4.0) [36] using 1 Mb 
bins.
Characterisation of primary tumours
Formalin-fixed and paraffin-embedded (FFPE) archival 
tumour blocks were analysed by immunohistochemistry 
by collecting 4 μm sections on Superfrost charged slides 
(ThermoScientific). After drying overnight at 37 °C, sam-
ples were processed using a Ventana Benchmark immu-
nohistochemistry platform (Roche) with antibodies 
against p53 (Agilent cat#7001, RRID: AB_2206626, 1:50), 
CK7 (Agilent cat#7018, RRID: AB_2134589, 1:250), PAX8 
(Roche cat#760–4618, 1:100). Heat induced epitope 
retrieval was performed using CC1 (Roche), incubating 
samples at 95 °C for 36, 52, and 40 min for p53, CK7 and 
PAX8, respectively. Antibodies were incubated at 37 °C 
for 32, 40 and 32 min for p53, CK7 and PAX8, respec-
tively. p53 and CK7 were detected using Ultraview uni-
versal DAB kit (Roche), while PAX8 was detected using 
Optiview universal DAB kit (Roche), all as per manufac-
turer’s instructions. Sections were counterstained using 
Haematoxylin II (Roche) for 12 min and bluing reagent 
(Roche) for 8 min. Slides were imaged using the EVOS FL 
Auto 2 Imaging System (Invitrogen), using a × 10 or × 40 
objective lens under bright field, and processed using 
Adobe Photoshop.
NanoString of ovarian cancer cell lines
RNA was extracted using RNeasy Plus Mini kit (Qiagen) 
as per manufacturer’s instructions. 100 ng RNA was pro-
vided at concentration of 4 ng/μl to the Genomic Tech-
nologies Core Facility at University of Manchester for 
analysis using the NanoString nCounter Analysis Sys-
tem. Twenty-five replication genes, 25 mitotic genes, 25 
apoptotic genes (Fig.  4B) and 4 reference genes as nor-
malisation controls appropriate for use in ovarian cancer 
(RPLP0, PPIA, IPO8, TBP) were analysed using nSolver™ 
Analysis Software 4.0., which generated normalised tran-
script counts.
Analysis of mitotic, DNA replication and apoptotic gene 
expression in RNAseq datasets from the CCLE and Klijn 
et al., (2015)
Previous analysis utilised gene expression microarray 
profiling from the CCLE to identify ovarian cancer cell 
lines with low expression of DNA replication genes [26, 
38]. Here, we updated this analysis to utilise the more 
recent RNAseq performed by the CCLE [39] (Fig.  4C). 
Briefly, read counts were obtained from the Broad Insti-
tute data portal (https:// porta ls. broad insti tute. org/ ccle). 
The R package DESeq2 (v1.26.0) was used to normal-
ise and apply a variance stabilising transformation to 
the assembled read count matrix, followed by z-score 
transformation.
We additionally utilised read counts for the panel of 
10 ovarian cancer cell lines of the same DNA replica-
tion, mitotic and apoptotic gene lists from a pan-cancer 
cell line RNAseq study [40] (GEO accession number 
GSE40788). Raw read counts were treated as described 
previously. This revealed higher expression of these genes 
in OV56 cells than indicated in the CCLE data set, in 
agreement with our NanoString data (Fig. S4A).
RNA‑sequencing and analysis
RNA was extracted using RNeasy Plus Mini kit (Qiagen), 
quantified using a Qubit fluorometer (Life Technologies) 
and quality/integrity assessed using a 2200 TapeStation 
(Agilent Technologies). Sequencing libraries were then 
generated using the TruSeq® Stranded mRNA assay (Illu-
mina, Inc.) according to the manufacturer’s protocol. 
Adapter indices were used to multiplex libraries, which 
were pooled and paired-end sequenced on an Illumina 
HiSeq4000 instrument. The output data was demulti-
plexed (allowing one mismatch) and BCL-to-Fastq con-
version performed using Illumina’s bcl2fastq software. 
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Overlapping paired reads were merged using BBMerge, 
and trimming and filtering was done using BBDuk, both 
from BBMap v36.32. The filtered reads were mapped to 
the human reference sequence analysis set (hg38/Dec. 
2013/GRCh38) from the UCSC browser, using STAR 
v2.7.2b [41]. The genome index was created using the 
comprehensive Gencode v32 gene annotation. The num-
ber of reads per gene were counted using ‘--quantMode 
GeneCounts’ within the STAR command.
Of the 32 OCMs profiled for PARGi and PARPi sen-
sitivity, 29 have been analysed by RNAseq across 6 
sequencing runs [13, 30, 42]. Data analyses in R was per-
formed using v3.6.2 and Bioconductor v3.10. The DESeq2 
(v1.26.0) package was used to apply a variance stabilising 
transformation to the assembled read count matrix [43]. 
A z-score transformation was then applied and OCMs 
ranked by the sum of z-scores for 25 mitotic, DNA rep-
lication and apoptotic gene (lists as described above). 
Heatmaps were created using ComplexHeatmap v2.6.2 
[44]. PARGi-sensitivity was defined using the colony for-
mation assay data in Fig. S6B, whereby treated OCMs 
with < 50%, ≥50–< 90%, and ≥ 90% colony area of control 
are defined as PARGi-sensitive, partially PARGi-sensitive, 
and PARGi-resistant, respectively.
Quantification and statistical analysis
Statistical analysis was carried out using GraphPad Prism 
8 Software. P values were designated as follows: * < 0.05, 
** < 0.01, *** < 0.001, **** < 0.0001, ns p > 0.05. Details of 
statistical analyses are described in the figure legends.
Results
Identification of PARGi sensitive and resistant ovarian 
cancer cell lines
To analyse the molecular mechanisms underlying PARGi 
sensitivity, we assembled a panel of ten ovarian can-
cer cell lines: OVMANA, Kuramochi, OVISE, RMG1, 
OV56, CAOV3, COV362, OVCAR3, OVSAHO and 
COV318 (Fig.  1A). While six of these cell lines have 
genetic hallmarks of HGSOC, in particular TP53 muta-
tions (Fig. 1A), OVMANA, OVISE, RMG1 and OV56 are 
more representative of ovarian clear cell carcinoma [30, 
45]. Nevertheless, we reasoned that analysing a panel 
of epithelial ovarian cancer cell lines with potential for 
PARGi sensitivity would provide insight into the intrinsic 
vulnerabilities responsible for PARGi sensitivity, and in 
particular provide insight into whether PARGi sensitivity 
was occurring via a common mechanism.
Previously, we showed that Kuramochi, OVMANA 
and RMG1 are PARGi sensitive in long-term colony 
formation assays, while COV362, CAOV3, OVCAR3, 
OVSAHO and COV318 were resistant in a short-
term proliferation assay. While OV56 was identified as 
resistant by colony formation assay, OVISE was also 
classified as resistant because PARGi treatment failed to 
induce pan-nuclear γH2AX [26]. Note however that in 
our previous study, analysis of OVISE was challenging 
due to technical issues, which we have now overcome. To 
systematically compare PARGi sensitivity, all ten cell lines 
were now analysed in long-term colony formation assays 
following exposure to 1 μM PARGi for 24, 48, 72 h or 
continuously, and colony area quantitated. Examination 
of continuously treated cells confirmed that Kuramochi, 
OVMANA and RMG1 are indeed PARGi sensitive (Fig. 
S1A, B). However, in contrast to our previous report, this 
latest analysis shows that OVISE is also PARGi sensitive. 
Outgrowth of OVMANA, Kuramochi and OVISE was 
also inhibited following drug exposure for 48 and 72 h, 
while RMG1 was not (Fig. S1C). In line with our previous 
study, growth of OV56, CAOV3, OVCAR3, OVSAHO 
and COV318 was not markedly suppressed even in the 
continuous presence of PARGi, while COV362 growth 
was partially suppressed (Fig. S1B). In addition, two out 
of four PARGi-sensitive cell lines were resistant to PARPi 
(Kuramochi and RMG1), while four out of six PARGi-
resistant lines were sensitive to PARPi (Fig. S1A, G, H), 
confirming differential sensitivity in some cases, despite 
both inhibitors targeting PARylation.
To independently analyse PARGi sensitivity, each cell 
line harbouring a GFP-tagged histone was analysed by 
time-lapse microscopy, over a 120-h period, in the pres-
ence of increasing concentrations of PARGi (Fig. S1D). 
Proliferation curves were then analysed to determine 
nuclear doubling rates and in turn calculate  EC50 val-
ues (Fig. S1E). COV318, OVSAHO, OVCAR3, COV362 
and CAOV3 were largely unaffected even at very high 
concentrations of PARGi, yielding high or indetermi-
nant  EC50 values (Fig. S1F). By contrast proliferation of 
RMG1, OVMANA and OVISE was strongly inhibited, 
yielding  EC50 values in the micromolar range (Fig. S1F). 
Consistent with our previous analysis, Kuramochi were 
particularly sensitive with an  EC50 value of 46 nM.
To integrate these two data sets, we plotted  EC50 val-
ues from the proliferation assays against colony area in 
the continuous presence of PARGi (Fig. 1B). This clearly 
highlights OVMANA, Kuramochi, OVISE and RMG1 
as PARGi-sensitive, and OVSAHO, CAOV3, OVCAR3 
and COV318 as PARGi-resistant. COV362 and OV56 are 
more ambiguous. While OV56 yields an  EC50 of ~ 4.5 μM, 
these cells clearly form colonies in 1 μM of PARGi and 
closer inspection reveals that these colonies are less 
dense than controls (Fig. S1A), suggesting that although 
PARGi slows OV56 proliferation it does not block it 
enough to prevent outgrowth. With an indeterminant 
 EC50, COV362 appears PARGi-resistant, and closer 
inspection reveals large colonies indicating outgrowth 
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(Fig. S1A). Thus, we conclude that both COV362 and 
OV56 are PARGi resistant. In summary, taking together 
the long-term colony formation assay and the short-term 
nuclear proliferation assay, we conclude that OVMANA, 
Kuramochi, OVISE and RMG1 are PARGi-sensitive while 
OV56, CAOV3, COV362, OVCAR3, OVSAHO and 
COV318 are PARGi-resistant.
PARGi stabilises PAR chains in both sensitive and resistant 
cell lines
A possible explanation for PARGi resistance could simply 
be that the PARGi fails to engage with its target in resist-
ant cells, for example due to drug efflux mechanisms. 
Therefore, we sought to determine whether PARGi was 
indeed inhibiting PARG activity in all ten cell lines, by 
measuring the accumulation of PAR chains. Analy-
sis of single cells by immunofluorescence microscopy 
showed that in all cell lines, exposure to PARGi increased 
the intensity of nuclear PAR staining (Fig. S2A–C). 
Importantly, increased PAR staining was blocked by co-
treatment with an equimolar concentration of PARPi, 
indicating that accumulation of PAR chains was depend-
ent on PARP activity (Fig. S2A–C). Immunoblotting also 
revealed increased PAR levels in PARGi-treated versus 
untreated cells, with accumulation of higher molecular 
weight PAR species indicating stabilisation of PAR chains 
(Fig. S2D–F). However, the very high molecular weight 
PAR species did not accumulate in OV56 or Kuramo-
chi, and indeed, there is inter-line variation in PAR-chain 
dynamics (Fig. S2E). For OV56, although increased PAR 
staining with PARGi treatment was seen by microscopy, 
the increase was minimal by immunoblotting. This dis-
parity is perhaps due to differences in assay sensitivity 
and/or arises from observing individual cells versus the 
whole population. Nevertheless, the two approaches sup-
port that PARGi resistance is not explained by a failure to 
stabilise PAR chains, but rather by an ability to tolerate 
the presence of stabilised PAR chains.
Fig. 1 Identification of PARGi‑sensitive and ‑resistant ovarian cancer cell lines. A Mutational profile of ovarian cancer cell line panel [45]. B XY 
plot showing correlation between  EC50 and colony formation with PARGi treatment. Values derived from ≥2 experiments  (EC50) or ≥ 3 (colony 
formation). See also Fig. S1
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PARGi sensitivity is accompanied by markers of replication 
stress
Having established that PAR chains accumulate with 
PARGi treatment in all ten cell lines, we asked whether 
PARGi sensitivity occurs via a similar mechanism, in 
particular via DNA replication catastrophe. Previously, 
we showed that PARGi-sensitive Kuramochi cells dis-
played features consistent with persistent replication 
stress, DNA damage and eventually replication catas-
trophe upon prolonged exposure to PARGi [26]. If this 
phenomenon is a common cause of PARGi sensitivity, 
we reasoned that these features should also manifest in 
other sensitive lines, but not resistant lines. To test this, 
we measured accumulation of three well recognised 
markers of replication stress, namely γH2AX foci, RPA 
foci, and nuclear phospho-KAP1 [29, 46, 47] using high-
throughput immunofluorescence microscopy (Fig.  2A, 
B and S3A, B). After 48 h of exposure to PARGi, γH2AX 
foci were substantially and significantly increased in the 
sensitive lines OVISE, Kuramochi and OVMANA, but 
not in the six resistant cell lines (Fig. 2A and S3A, B). By 
72 h, cells with pan-nuclear γH2AX staining also became 
apparent (Fig. 2A, B). Induction of RPA1 foci and nuclear 
phospho-KAP1 showed a similar trend (Fig.  2A, B and 
S3A), confirming a correlation between PARGi sensitiv-
ity and markers of replication stress. To independently 
analyse replication stress, we analysed cell populations 
by immunoblotting to measure phosphorylation of Chk1, 
normalised to total Chk1, and using the ribonucleotide 
reductase inhibitor hydroxyurea (HU) as a positive con-
trol (Fig.  2C). This was initially done by chemilumines-
cent western blot (Fig. S3C), but subsequently repeated 
using LI-COR system to enable quantification (Fig.  2C, 
S3D). Because Chk1 phosphorylation in response to HU 
exhibited substantial variation between the cell lines, we 
expressed the phosho-Chk1/total-Chk1 ratio as a per-
centage of the HU-induced maximum. This shows that 
PARGi induced strong Chk1 phosphorylation responses 
in three of the sensitive lines RMG1, OVISE and 
Kuramochi, but not in the resistant lines (Fig. S3C, D), 
further suggesting a correlation between PARGi sensitiv-
ity and replication stress.
We did notice a few exceptions to this overall trend. 
While RMG1 cells are sensitive and showed a substantial 
fold change in RPA foci and strongly induced phosho-
Chk1, they showed only modest increases in γH2AX 
foci and phosphorylated-KAP1 (Fig. S3A, D). Also, while 
CAOV3 cells are PARGi resistant, they showed induc-
tion of RPA1 foci, but not the other markers, suggesting 
this level of replication stress is tolerated sufficiently to 
allow growth (Fig. S3A). Indeed, it has previously been 
reported that PARG is required for recovery from per-
sistent, but not short-term replication stress [48]. These 
exceptions highlight the limitations of relying on a sin-
gle marker of replication stress. Therefore, we integrated 
these four datasets by plotting the fold changes of γH2AX 
foci versus RPA foci, phospho-KAP1 and phospho-Chk1 
(Fig. 2D). This analysis shows a clear demarcation of sen-
sitive and resistant cell lines, with OVISE, Kuramochi, 
RMG1 and OVMANA segregated from the six resistant 
cell lines. Thus, in toto, these observations demonstrate 
that PARGi sensitivity does reflect a common mechanism 
in ovarian cancer cell lines, namely persistent replication 
stress leading to replication catastrophe.
PARGi induces replication fork asymmetry in sensitive cell 
lines
We previously showed that inhibiting PARG causes 
DNA replication fork asymmetry in sensitive Kuramo-
chi cells, but not resistant OVCAR3 cells [26], reflecting 
the role of PARG in restarting stalled replication forks. 
Having established that all four sensitive lines demon-
strated features of replication stress when exposed to 
PARGi, we asked whether this was accompanied by per-
sistent fork stalling, which we assessed using fork asym-
metry assays [49]. Following a 48-h exposure to PARGi, 
cells were pulsed with BrdU to label active DNA replica-
tion forks, then chased with IdU to measure the speed 
(See figure on next page.)
Fig. 2 PARGi sensitivity is accompanied by markers of replication stress and the DNA damage response. A Representative images of RPA1 and 
γH2AX foci in response to 48 h of 1 μM PARGi treatment or DMSO (Control) in PARGi‑resistant (COV318) and PARGi‑sensitive (OVMANA) cell lines 
(upper). RPA1 and pan‑nuclear γH2AX staining also shown in PARGi‑sensitive OVISE cells following 72 h PARGi treatment (lower). Scale bars: 20 μm. B 
Representative images of pan‑nuclear pKAP1 and γH2AX staining in PARGi‑resistant (COV362) and PARGi‑sensitive (OVISE) cell lines following 72 h of 
1 μM PARGi treatment. Scale bar: 20 μm. C Representative immunoblot Li‑COR image for PARGi‑resistant (OVCAR3) and PARGi‑sensitive (Kuramochi) 
cell lines; cells were treated for 48 h with 1 μM PARGi (Gi) or DMSO as a negative control (C), or for 2 h with 2 mM hydroxyurea (H) as a positive 
control. D Bubble plot showing fold‑change in RPA1 foci, γH2AX foci, pan‑nuclear pKAP1 and Chk1 phosphorylation in response to PARGi treatment. 
Mean of n ≥ 3 biological replicates for each parameter quantified using single‑cell immunofluorescence microscopy. Bubble size represents 
pChk1, bubble colour represents pKAP1. (E) Schematic of DNA fibre experimental strategy. (F) Exemplar fibres in PARGi‑resistant (COV318) and 
PARGi‑sensitive (OVMANA) cell lines. Scale bar: 10 μm. (G) Mean % asymmetric forks are shown on the left. The exemplar graphs on the right show 
correlation between R and L fork lengths. Dotted lines represent 33% cut‑off, beyond which forks are considered asymmetric (% asymmetry for 
replicate shown in respective graph bottom right corner). Statistics: Mean of 3 biological replicates, with ≥50 forks measured per cell line, per 
condition. 2‑way ANOVA with Sidak post‑hoc test, selected comparisons were between PARGi treated values and DMSO control within each cell 
line. Error bars represent SEM. * p < 0.05. See also Fig. S3
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of left and right cognate forks (Fig. 2E, F). The three cell 
lines in the panel with the highest fold-change (1.7–2.3 
fold) in fork asymmetry following PARGi-treatment 
are PARGi-sensitive (OVMANA, Kuramochi, RMG1; 
Fig.  2G); whereas COV362 cells, despite a fold-change 
of 1.5, are PARGi-resistant. Intriguingly, these four cell 
lines possess BRCA1/2 mutations or deletions (Fig. 1A); 
accordingly, fork asymmetry following PARGi-treatment 
could be due to an absence of both PARG- and HR-medi-
ated fork restart [27]. However, PARGi-resistant OVS-
AHO has a homologous deletion in BRCA2 and does 
not show increased fork asymmetry following treatment. 
Fig. 2 (See legend on previous page.)
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Furthermore, asymmetry only increased marginally in 
PARGi-sensitive OVISE, which is BRCA1/2 wild-type, 
although these cells have intrinsically high levels of asym-
metry, possibly indicating an existing fork-restart vulner-
ability in these cells (Figs. 1A and 2G). The level of fork 
asymmetry conferring PARGi-sensitivity may there-
fore differ between cell lines, and is likely modulated by 
other factors in addition to HR status, such as the abil-
ity to utilise dormant replication origins. Indeed, there 
is variation in basal level of fork asymmetry across the 
panel (Fig. 2G). Nevertheless, we conclude therefore that 
PARGi sensitivity generally is accompanied by an induc-
tion of DNA replication fork asymmetry, indicating per-
sistent fork stalling, further supporting the notion that 
PARGi sensitivity is due to persistent replication stress.
PARGi suppresses mitotic entry in sensitive cell lines
Persistent replication stress activates intra-S and  G2/M 
checkpoints, thereby blocking cell cycle progression, and 
in particular inhibiting entry into mitosis. Indeed, we 
previously showed that a substantial fraction of PARGi-
treated Kuramochi cells underwent a Wee1-dependent 
 G2 arrest, and that those cells that did progress through 
mitosis often did so abnormally, and subsequently died 
[26]. To determine whether a similar cell fate was shared 
by other PARGi-sensitive lines, we analysed the panel of 
ten cell lines using time-lapse microscopy for 115 h and 
generated cell fate profiles [34]. In the absence of PARGi, 
the vast majority of cells in each line underwent multi-
ple successful divisions and were alive at the end of the 
experiment (Fig.  3A). Significantly, PARGi treatment of 
the sensitive cell lines resulted in an increased propor-
tion of cells that did not enter mitosis, with 48, 32 and 
51% of OVMANA, Kuramochi and RMG1, respectively, 
blocking in interphase (Fig. 3A). This phenotype was not 
observed in the resistant cell lines where the majority of 
cells continued to complete multiple cell divisions when 
treated with PARGi.
Interestingly, in the four sensitive cell lines, a small pro-
portion of cells did not enter mitosis in the absence of 
PARGi, consistent with these cells exhibiting an underly-
ing vulnerability that is markedly exacerbated by inhibi-
tion of PARG. Of the resistant lines, a small proportion of 
COV318 cells also did not enter mitosis in the absence of 
PARGi, but in contrast to the sensitive lines, this did not 
increase substantially upon exposure to PARGi.
In most of the cultures analysed, a fraction of cells 
underwent abnormal mitoses and/or cell death and this 
phenotype was exacerbated by PARGi in sensitive but not 
resistant lines. In particular, while only 14% of PARGi-
treated OVISE cells blocked in interphase, the number 
of cells undergoing abnormal mitoses and/or cell death 
increased from 17 to 46% (Fig. 3A). Although the analy-
ses above indicate that OV56 is PARGi-resistant, the cell 
fate profiling indicates that drug exposure increases the 
number of abnormal mitoses from 23 to 35% (Fig.  3A), 
possibly reflecting a synthetic effect with the prolonged 
cell culture and/or imaging conditions.
To quantitate these PARGi effects on mitotic poten-
tial, we counted the number of productive cell divisions 
in control and drug-treated populations. In sensitive cell 
lines, PARGi dramatically reduced the number of normal 
mitoses, by an average of 73%, compared with a minor 
reduction (11% on average) in resistant lines (Fig.  3B). 
Thus, considering both the cell fate profiles and the quan-
titation of successful divisions, we conclude that sensitiv-
ity to PARGi is accompanied by a dramatic loss of mitotic 
potential, in particular a pre-mitotic block, consistent 
with activation of intra-S and  G2/M checkpoints due to 
persistent replication stress.
PARGi sensitivity correlates with replication stress
The analyses described above show that markers of rep-
lication stress (Fig.  2A–D), fork asymmetry (Fig.  2E–F) 
and a pre-mitotic block (Fig. 3), associated with increased 
nuclear size and reduced cell count (data not shown), also 
appear to correlate with PARGi sensitivity. To confirm 
this, we integrated the various datasets by scaling each 
parameter so that the most resistant and sensitive lines 
scored 1 and 0 respectively (Fig.  4A). These were then 
averaged to yield an overall sensitivity score and rank 
ordered. Importantly, the various cell biological param-
eters clearly align with sensitivity as defined by the col-
ony formation and short-term proliferation assays, with 
COV318, OVSAHO, OVCAR3 and COV362 ranking as 
the most resistant lines, and OVMANA, Kuramochi and 
OVISE the most sensitive. Of the sensitive lines, RMG1 
ranks as the least sensitive and indeed, as noted above, 
this line requires continuous exposure for fully penetrant 
Fig. 3 PARGi suppresses mitotic entry in sensitive cell lines. A Cell fate profiling, showing cell behaviour over 115 h treatment with 1 μM PARGi or 
DMSO (Control). Each horizontal line represents a single cell, with the colours indicating cell behaviour. Following mitosis, one daughter cell was 
chosen at random to continue the analysis. No mitotic entry does not include death in interphase where mitosis does not take place. Abnormal 
mitosis includes cell division abnormalities such as slippage (where cells enter mitosis, but exit without division), fusion (where daughter cells 
appear to separate but subsequently join back together), tripolar cell divisions and division of binuclear cells. B The % of total normal mitoses in 
PARGi‑treated compared with DMSO controls. Mean of ≥2 biological replicates. Statistics: total normal mitoses in DMSO‑treated compared with 
PARGi‑treated cells was compared by 2‑way ANOVA with Sidak post‑hoc test. Error bars represent SEM. ***p < 0.001, ****p < 0.0001
(See figure on next page.)
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Fig. 3 (See legend on previous page.)
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Fig. 4 PARGi‑sensitive cell lines have lower expression of DNA replication genes. A PARGi‑sensitivity assay results summarised as a heatmap. 
Assay results (except  EC50 values) were scaled from 0 to 1, averaged, and cell lines rank ordered accordingly. γH2AX at 48 h is based on nuclear 
foci quantification. γH2AX at 72 h is based on nuclear intensity. B NanoString DNA replication, mitotic and apoptotic gene Z‑scores of cell lines 
represented by heatmaps where red = high expression; white = average expression and blue = low expression. C Box‑whisker plots (min–max) for 
DNA replication genes Z‑scores shown for NanoString compared with RNA‑sequencing (RNAseq) data from the CCLE [39]. See also Fig. S4
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inhibition (Fig. S1A–C). Of the resistant lines, OV56 is 
the least resistant and, again as noted above, although 
colonies form in the presence of PARGi, they are less 
dense than control colonies (Fig. S1A, B). CAOV3 are 
also at the more ‘sensitive’ end of the resistant spectrum 
and interestingly, these cells do display increased RPA 
foci when exposed to PARGi (Fig. S3A), suggesting that 
while PARGi does induce replication stress, it is resolved 
sufficiently to allow efficient recovery. Nevertheless, this 
integrated analysis confirms that PARGi sensitivity does 
indeed correlate with markers of replication stress in 
ovarian cancer cell lines, suggesting a common underly-
ing mechanism. Moreover, because PAR chains are stabi-
lised in all cell lines analysed (Fig. S2C, D), an important 
corollary is that resistant cell lines can efficiently com-
plete DNA replication despite the presence of stabilised 
PAR chains.
PARGi sensitivity correlates with lower expression of DNA 
replication genes in cell lines
The strong correlation between markers of replication 
stress and PARGi sensitivity supports our previous con-
clusion that sensitive cell lines harbour an underlying 
DNA replication vulnerability that makes them particu-
larly dependent on PARG activity to re-start stalled rep-
lication forks [26]. While the nature of this vulnerability 
remains to be determined, when we previously inter-
rogated CCLE microarray data, we noted that in addi-
tion to Kuramochi, the expression levels of a number 
of DNA replication genes was lower in RMG1, OV56, 
OVMANA and OVISE cell lines compared with resist-
ant lines [26]. Of these four, we previously showed that 
RMG1 and OVMANA are PARGi-sensitive, and here 
we demonstrate that OVISE is also sensitive. However, 
while OV56 is the most ‘sensitive’ of the resistant lines, 
it is resistant despite apparent low expression levels of 
DNA replication genes. To address this anomaly, we set 
out to independently validate the expression levels of 25 
DNA replication genes using a custom NanoString Code-
Set (Fig. 4B) and compare the overall expression of these 
genes with more recent RNA-sequencing (RNAseq) 
from the CCLE project [39] (Fig. 4C). NanoString analy-
sis confirmed that expression of the 25 DNA replication 
genes is lower in PARGi-sensitive than -resistant lines, 
and for eight cell lines the CCLE and NanoString data 
significantly correlated (Fig. S4A). While the correlation 
between NanoString and CCLE for RMG1 is not signifi-
cant, both find that this PARGi-sensitive line has lower 
expression of these genes than resistant lines. However, 
in contrast with the CCLE data, we find that OV56 have 
relatively high expression of the DNA replication genes 
in line with other resistant lines (Fig.  4C, S4A). Inter-
estingly, while the more recent RNAseq data from the 
CCLE project is consistent with their previous microar-
ray data [38, 39], an independent RNAseq study of cancer 
cell lines also indicates higher expression of DNA repli-
cation genes in OV56 [40]. Indeed, the OV56 data from 
Klijn et  al., significantly correlated with our NanoString 
expression data, but not the CCLE data (Fig. S4A). Aside 
from the anomaly of OV56, two independent RNAseq 
datasets [39, 40] and our NanoString-based analy-
sis therefore indicate that cell lines that are sensitive to 
PARGi tend to have lower expression levels of a number 
of DNA replication genes.
If PARGi-sensitivity specifically correlates with DNA 
replication gene expression, we expected the expres-
sion level of genes involved in other processes not to 
be associated with sensitivity. To test this, we expanded 
our analysis to include 25 mitotic genes and 25 apop-
totic genes, based on NanoString CodeSets we used 
previously [50]. While apoptotic gene expression was 
variable amongst both sensitive and resistant cell lines, 
expression of the mitotic genes was lower in PARGi-
sensitive versus -resistant lines (Fig. 4B, S4A). However, 
we also observed a striking correlation between expres-
sion of replication and mitotic genes in our cell line panel 
(NanoString:  R2 = 0.87, p < 0.0001 [not shown]; CCLE: 
 R2 = 0.96, p < 0.0001) (Fig. S4B). Replication and mitotic 
gene expression also correlated in a wider cohort of 747 
cancer cell lines within the CCLE database  (R2 = 0.72, 
p < 0.0001), but this was not observed for replication ver-
sus apoptotic genes  (R2 = 0.081) (Fig. S4B). Therefore, 
while the NanoString analysis builds on our previous 
analysis [26], showing association between low expres-
sion of DNA replication genes and PARGi sensitivity, we 
cannot rule out a wider cell cycle control gene expression 
phenotype.
Differential sensitivity to PARPi and PARGi
As PARG acts as a direct counterbalance to PARP-1/2, 
and further therapeutic strategies are needed for disease 
with inherent or acquired PARPi resistance, we won-
dered whether PARGi-sensitive cell lines showed dif-
ferential sensitivity to PARPi, and vice versa. In terms of 
PARPi sensitivity, using a short-term confluence assay, 
we previously showed that OVSAHO, COV318, COV362 
and CAOV3 were PARPi-resistant, whereas OVCAR3 
was sensitive [26]. Because long-term target engagement 
can be required to observe synthetic lethality between 
cells with a BRCA1/2 mutation and Olaparib [28], we re-
visited this and compared PARPi and PARGi sensitivity 
in long-term colony formation assays with continuous 
drug exposure. Of these four lines, with the exception 
of COV318, all showed a reduction in outgrowth in 
response to PARPi (Fig. S1G). By contrast, and in agree-
ment with our previous report, OV56, Kuramochi and 
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RMG1 were relatively resistant to PARPi. Notably, 
OVISE and OVMANA were sensitive to both PARPi and 
PARGi. Thus, we conclude that of the ten ovarian can-
cer cell lines analysed here, four are PARPi-sensitive and 
PARGi-resistant; two are PARGi-sensitive and PARPi-
resistant; two are sensitive to both treatments and two 
are resistant to both (Fig. S1H). This implies that sensitiv-
ity to PARGi and PARPi is neither mutually exclusive nor 
overlapping, indicating that the determents of sensitivity 
are context dependent. In this regard OV56 is an inter-
esting case – while categorised as PARGi-resistant, it is 
the least ‘resistant’ of the resistant lines and PARGi expo-
sure is clearly not completely inconsequential: the short-
term proliferation assay yields high  EC50 values for PARPi 
and PARGi (Fig. S1F, G), and the colonies are less dense 
than controls for the PARGi-treated culture (Fig. S1A). 
In contrast, in response to PARPi, it forms robust colo-
nies (Fig. S1A). Thus, despite the intimate relationship 
between PARP and PARG activities, and despite the com-
plexities described above, a differential sensitivity clearly 
manifests across multiple cell lines, indicating that PARG 
inhibitors may offer an alternative therapeutic option to 
target a subset of ovarian cancers, such as HRP tumours 
that are less likely to respond to PARPi.
Identification of PARGi‑sensitive patient‑derived ovarian 
cancer models
Having demonstrated that PARGi sensitivity in estab-
lished ovarian cancer cell lines arises due to replication 
catastrophe, we determined the impact of PARGi on a 
panel of 32 patient-derived OCMs from a living biobank 
focused on women treated at The Christie Hospital [13]. 
In contrast to established cell lines, these OCMs are 
clinically annotated and available for analysis at low pas-
sage. Seven OCMs were described previously [13], and 
with 25 additional OCMs described here (Supplementary 
Table  1). Importantly, these new OCMs also displayed 
the features of HGSOC, namely nuclear atypia, universal 
expression of CK7 and PAX8, aberrant p53 expression, 
TP53 and BRCA1/2 mutations, and extensive chromo-
somal instability (Fig. S5; Supplementary Table  1). To 
screen for PARGi sensitivity, the panel was exposed to 
1 μM drug for 96 h and colony area (ca) measured after 
≥2 weeks (Fig. S6A). Of the 32, 15 were largely unaf-
fected (ca ≥ 90%), 10 partially affected (50% ≤ ca < 90%) 
and seven substantially affected (ca < 50%) (Fig. S6B). Of 
these seven sensitive OCMs, 191, 109 and 246 were then 
further analysed in parallel with four resistant OCMs, 
namely 99, 105, 152 and 46–3 (Fig. 5A, B). First, we con-
firmed relative sensitivity, both in a colony formation 
assay in response to continuous PARGi exposure (Fig. 
S6D, E), and in a time-lapse microscopy-based short-
term proliferation assay tracking GFP-tagged nuclei 
(Fig. 5C). Note that an N-methylated analogue of PARGi 
with minimal activity in  vitro [28] was inactive against 
OCMs 191, 109 and 246 (Fig. S7), consistent with sensi-
tivity due to on-target inhibition of PARG. Interestingly, 
there was no obvious correlation with cisplatin or pacli-
taxel sensitivity (Fig. 5D), and while OCMs 109 and 246 
were resistant to the PARP inhibitors Olaparib and Nira-
parib (Fig.  5E, F), OCM.191 was PARPi-sensitive (Fig. 
S6D, E). Indeed, the screen identified eight PARPi-sen-
sitive OCMs, five of which were PARGi-resistant, while 
191, 80–2, 59–3 were PARGi-sensitive (Fig. S6A–C). 
Thus, in summary, out of 32 patient-derived OCMs, we 
identified seven sensitive to the PARGi and eight sensi-
tive to PARPi, including three sensitive to both.
PARG inhibition also induces replication catastrophe 
in sensitive OCMs
Having identified PARGi-sensitive OCMs, we asked 
whether they also showed the hallmarks of replica-
tion catastrophe upon PARG inhibition. As with the 
established cell lines, PARGi stabilised PAR chains in 
both PARGi-sensitive and -resistant OCMs in a PARP-
dependent manner (Fig. 6A, B), consistent with the abil-
ity of resistant cells to tolerate persistent PAR chains. 
Importantly, PARGi induced hallmarks of replication 
catastrophe in two of the three sensitive OCMs ana-
lysed (109 and 246), which was evidenced by significant 
increases in gH2AX, pKAP1, RPA foci, Chk1 phospho-
rylation and a pre-mitotic cell cycle block (Fig.  6C–H, 
S8A, B). By contrast, the PARGi-resistant OCMs did 
not display these hallmarks. Thus, the two OCMs that 
are sensitive to PARGi, but PARPi-resistant, do indeed 
undergo replication catastrophe in a manner similar to 
the PARGi-sensitive established cell lines. Surprisingly, 
despite OCM.191 being sensitive to PARGi in both short 
and long-term assays, it did not display the features typi-
cal of replication catastrophe. A pre-mitotic block was 
evident in a small proportion of cells following PARGi 
treatment and, although most cells underwent mitosis, 
there were fewer total mitoses in PARGi-treated than 
control cells (Fig. S8A). This was partly owing to a longer 
interphase and, despite a similarly high rate of apop-
totic events both with and without treatment, apop-
tosis tended to occur earlier in PARGi-treated cells. In 
addition, OCM.191 had an intermediate  EC50, similar 
to OV56 in the cell line panel, which similarly showed 
moderate sensitivity to PARGi in short and long-term 
assays without features of significant replication stress 
with PARGi-treatment (Fig. 2D, S3).
Interestingly, OCM.191 is also PARPi-sensitive, and 
indeed it harbours a BRCA mutation and is possibly 
therefore HRD. Because HR defects may contribute to 
PARGi-sensitivity [22, 24], one possibility therefore is 
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that the defective HR may contribute to PARGi sen-
sitivity in this case. Interestingly, OCM.246 was also 
derived from a patient with a germline BRCA2 muta-
tion; however the patient received Olaparib main-
tenance monotherapy prior to biopsy sampling and 
the subsequent OCM harbours an intragenic BRCA2 
reversion predicted to restore the open reading frame 
[51, 52] (Supplementary Table  2), explaining ex  vivo 
PARPi resistance. Consistently, OCM.246 appears to be 
HRP, evidenced by the accumulation of Rad51 foci in 
irradiated G2 cells (Fig. S8C). By contrast, in the same 
assay, OCM.109 appears to be HRD, consistent with 
the notion that HR status is not a predictor of PARGi 
sensitivity [26]. Thus, while the relationship between 
HR status, PARPi and PARGi sensitivity is complex, 
we nevertheless conclude that the PARGi sensitivity in 
patient-derived OCMs 109 and 246 is indeed due to the 
induction of replication catastrophe.
Fig. 5 Drug sensitivity of OCMs. A Colony formation following 96 h of treatment with 1 μM PARGi or 1 μM PARPi or DMSO (Control). Representative 
images of 3 biological replicates. B Quantification of ca from (A) normalised to DMSO‑treated cells (Control) and represented as fold‑change. Mean 
of 3 biological replicates. C Proliferative Log  EC50 values for PARGi and PARPi (Olaparib) in panel of seven OCMs. Means of 3 biological replicates. D 
Proliferative Log  EC50 values for cisplatin and paclitaxel in panel of seven OCMs. Means of 3 biological replicates. E Proliferative Log  EC50 values for 
PARGi, Olaparib (PARPi) and Niraparib for PARGi‑sensitive OCMs (109 and 246). Mean of 3 biological replicates. F Dose‑response curves for PARGi, 
Olaparib (PARPi) and Niraparib for PARGi‑sensitive OCMs (109 and 246). Mean of 3 biological replicates. PRISM could not accurately calculate  EC50 for 
PARGi‑resistant cells, therefore for resistant OCMs the  EC50 was approximated as 50 μM (half the maximal concentration tested). Error bars represent 
SEM. Statistics: 1‑way ANOVA with Dunnett’s multiple comparisons test of PARGi versus Olaparib (P < 0.0001) and PARGi versus niraparib (P < 0.0001). 
* p < 0.05, ** p < 0.01, ****p < 0.0001. See also Supplementary Table 3, and Figs. S6 and S7
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DNA replication gene expression in OCMs does 
not correlate with PARGi‑sensitivity
Having demonstrated that PARGi-sensitivity was accom-
panied by replication catastrophe in two of the three sen-
sitive OCMs examined, we asked whether the expression 
levels of DNA replication genes correlated with sensitiv-
ity, as observed in the established cell lines (Fig. 4B). The 
DNA replication, mitotic and apoptotic genes exam-
ined using NanoString in the established cell lines were 
evaluated in 29 OCMs for which we have RNAseq data 
[13, 30, 42]. As with our Nanostring data and the CCLE 
data, the expression of DNA replication and mitotic 
genes was highly correlated (Fig. S9A). In addition, there 
was a gradient in DNA replication expression across the 
OCM panel, with OCMs 86 and 106 showing the high-
est and lowest aggregated Z-scores respectively (Fig. 7A). 
However, ranking the OCMs by overall expression of the 
DNA replication genes did not differentiate PARGi-sensi-
tive and -resistant OCMs (Fig. 7A, B). Similarly, ranking 
by mitotic and apoptotic genes also failed to differentiate 
PARGi sensitivity (Fig. S9B, C). This suggests that, in con-
trast to our earlier hypothesis [26], a DNA ‘replication 
stress’ gene expression signature may not be sufficient to 
serve as a predictive biomarker for PARG inhibitor sen-
sitivity in a clinical cohort of HGSOC. Below we discuss 
these results in the context of developing a predictive 
biomarker for PARGi sensitivity.
Discussion
We set out to address two questions: (1) whether PARGi-
sensitive ovarian cancer cells exhibit similar or differ-
ent phenotypes in response to PARG inhibition, and (2) 
whether PARGi sensitivity correlates with the expression 
levels of DNA replication genes. Our analysis of 10 estab-
lished ovarian cancer cell lines shows that indeed, the 
four PARGi-sensitive lines all displayed features of per-
sistent replication stress upon exposure to PARGi. More-
over, interrogating three independent gene expression 
data sets identified a clear correlation between PARGi 
sensitivity and expression of DNA replication genes. We 
also observed a replication catastrophe phenotype in two 
PARGi-sensitive patient-derived ex vivo OCMs; however, 
in contrast to the established cell lines, they did not dis-
play lower DNA replication gene expression relative to 
PARGi-resistant OCMs. Below, we discuss these obser-
vations in terms of (a) the mechanisms responsible for 
PARGi sensitivity, and (b) efforts to develop biomarkers 
capable of predicting PARGi sensitivity.
To address the first question, we initially focused on a 
panel of 10 established ovarian cancer cell lines, four of 
which are PARGi sensitive and the remaining six, resist-
ant. Upon PARG blockade, the four sensitive lines dis-
played features of replication stress and DNA damage, 
namely RPA and γH2AX foci, phosphorylation of Kap1 
and Chk1, and asymmetric DNA replication forks, in 
turn leading to replication catastrophe illustrated by pan-
nuclear γH2AX, pre-mitotic cell cycle arrest, reduced 
proliferation and suppressed outgrowth. By contrast, the 
resistant lines did not display these hallmarks, despite the 
stabilisation of PAR chains. Of the three PARGi-sensitive 
OCMs we analysed in detail, two also exhibited hall-
marks of replication catastrophe, extending our obser-
vations from established cell lines to patient-derived 
ovarian cancer cells that have not undergone extensive 
ex vivo proliferation [13]. Together, this recurrent repli-
cation catastrophe phenotype supports our prior hypoth-
esis that PARGi-sensitivity arises due to a pre-existing 
DNA replication vulnerability that prevents toleration 
of stabilised PAR chains. The nature of this vulnerability 
remains unclear but could reflect compromised repli-
some function, a notion supported by reduced DNA 
replication gene transcripts in sensitive lines. However, 
whether these genes are down-regulated due to active 
suppression of transcription is not clear. Alternatively, 
resistant cell lines may have actively up-regulated DNA 
replication genes, possibly as an adaptive response to 
oncogene-induced replication stress [53, 54]. In budding 
yeast, various adaptive mechanisms can increase fitness 
(See figure on next page.)
Fig. 6 Mechanism of PARGi sensitivity in OCMs. A Representative immunoblots showing PAR chain formation in OCMs following 96 h of treatment 
with DMSO (C), 1 μM PARPi (Pi) or 1 μM PARGi (Gi). B Quantification of PAR staining in response to PARGi (Gi) or PARGi co‑treated with PARPi (Gi + Pi) 
using single‑cell immunofluorescence microscopy, normalised to DMSO‑treated cells (Control). Mean of 3 biological replicates. Error bars represent 
SEM. C Quantification of γH2AX foci per nucleus and nuclear pKAP1 intensity after 72 h of 1 μM PARGi using single‑cell immunofluorescence 
microscopy, normalised to DMSO‑treated cells (Control) and represented as fold change. Mean of 3 biological replicates. Error bars represent SEM. 
Statistics: 2‑way ANOVA with Dunnett’s multiple comparisons test, selected comparisons were between drug treatments and DMSO control. D 
Representative images of pan‑nuclear γH2AX and pKAP1 immunofluorescence staining in OCM.109 after 96 h treatment with 1 μM PARGi. Scale bar: 
20 μm. E Quantification of RPA foci per nucleus after 48 h of 1 μM PARGi using single‑cell immunofluorescence microscopy, left panel normalised 
to DMSO‑treated cells (Control) and represented as fold change. Mean of 3 biological replicates. Error bars represent SEM. Statistics: 2‑way ANOVA 
with Dunnett’s multiple comparisons test, selected comparisons were between drug treatments and DMSO control. F Representative images of 
nuclear RPA foci immunofluorescence staining after 96 h of 1 μM PARGi. Scale bar: 10 μm. G Representative immunoblots of pChk1 expression in 
PARGi‑sensitive (109 and 246) and PARGi‑resistant (105) OCMs following 96 h of treatment with DMSO (C), 1 μM PARPi (Pi), 1 μM PARGi (Gi) or 10 Gy 
of ionising radiation (IR). Tao1 serves as loading control. H Cell fate profiling, showing cell behaviour over 120 h treatment with 1 μM PARGi or DMSO 
(Control). See Fig. 3 and Fig. S8. **p < 0.01, ***p < 0.001, ****p < 0.0001
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in response to replication stress [55], raising the possi-
bility that differential PARGi sensitivity reflects different 
responses to oncogenic replication stress. Thus, while 
adaption via up-regulating DNA replication genes could 
engender intrinsic PARGi resistance, adaptation via 
other mechanisms may leave cells vulnerable to PARG 
Fig. 6 (See legend on previous page.)
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blockade. Exploring the evolution of acquired PARGi 
resistance may shed light on this issue.
While our data strongly points to a DNA replication 
vulnerability, other mechanisms can also render cells 
dependent on PARG activity. By sequestering NAD+ 
in stabilised PAR chains, PARG inhibition was recently 
shown to cause metabolic catastrophe in glioma cell lines 
harbouring IDH1 mutations [56]. This study employed 
the same PARG inhibitor but with sensitivity observed 
at a five-fold higher drug concentration and only when 
used in combination with temozolomide, indicating 
that in this case, sensitivity is due to a ‘triple whammy’ 
effect requiring IDH1 mutation, DNA damage and PAR 
stabilisation. Interestingly, in our study, partial PARGi 
sensitivity in OV56 was not accompanied by overt rep-
lication stress. Similarly, PARGi-sensitive OCM.191 
did not show signs of replication stress with treatment. 
Whether this intermediate sensitivity is accounted for by 
NAD+ sequestration and metabolic catastrophe remains 
to be seen. Moreover, whether PARGi-induced metabolic 
catastrophe is distinct from or related to the DNA rep-
lication vulnerability mechanism is also unclear. Indeed 
– because, firstly NAD+ metabolism is required to pro-
duce NADP+, and subsequently nucleic acid precursors 
via the pentose-phosphate pathway [57, 58], and secondly 
nucleotide depletion increases replication stress – PARGi 
sensitivity could reflect a complex interplay between 
DNA replication and NAD+ vulnerabilities. For exam-
ple, at low doses, PARGi may deplete NAD+ sufficiently 
to perturb nucleotide synthesis resulting in replication 
stress that can only be buffered by cells that have adapted 
to oncogene-induced replication stress. By contrast, 
when combined with acute DNA damage at higher doses, 
PARGi may deplete NAD+ to the point that it perturbs 
NAD+ pathways more broadly, leading to metabolic 
catastrophe. An interesting corollary therefore is that 
PARGi-sensitising DNA replication vulnerabilities could 
arise due to upstream defects in supplying nucleotides 
to the replisome, which are exacerbated by PARG block-
ade. Exploring the interplay between NAD+ metabolism, 
nucleotide synthesis and DNA replication in the context 
of PAR dynamics will be important next steps.
Our second question regarding a potential correlation 
between PARGi sensitivity and expression levels of DNA 
replication genes was motivated by the quest to develop 
predictive biomarkers for PARGi sensitivity to enable 
patient stratification for clinical trials. Interrogating 25 
DNA replication genes in two independent RNAseq 
datasets and our NanoString analysis shows a clear corre-
lation; the four PARGi-sensitive ovarian cancer cell lines 
show reduced expression levels versus the resistant lines. 
If this correlation extended to patient-derived OCMs, 
Fig. 7 DNA replication gene expression in OCMs does not correlate with PARGi‑sensitivity. A Heatmap showing RNAseq of 29 OCMs ranked by sum 
of Z‑scores for 25 DNA replication genes where red = high expression; white = average expression and blue = low expression. B XY plot showing 
colony formation area and the sum of Z‑scores for the expression of 25 DNA replication genes from RNAseq of 29 OCMs. PARGi sensitivity as 
determined by colony formation assay (see Fig. S6B). Note: RNAseq was unavailable for OCMs 267, 250–2, and 162–2. See also Fig. S6 and S9
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then one could envision a ‘replication stress’ gene expres-
sion signature providing the basis of a biomarker [26]. 
However, we did not observe a similar effect in PARGi-
sensitive OCMs. There are various possible explana-
tions for the non-concordance between established cell 
lines and OCMs. One possibility is sample size; while 
the colony formation screen identified seven OCMs as 
potentially sensitive, only OCMs 109 and 246 were par-
ticularly sensitive with nanomolar  EC50 values. As our 
living biobank grows, it will be important therefore to 
identify additional PARGi-sensitive OCMs to further test 
whether DNA replication gene expression correlates with 
sensitivity. A second possibility is that analysing estab-
lished cell lines is complicated by different ovarian cancer 
subtypes. While PARGi-sensitive Kuramochi is HGSOC-
derived, the three other sensitive cell lines (OVMANA, 
OVISE and RMG1) represent the clear cell subtype [30, 
45]. Thus, the correlation may reflect a clear cell phenom-
enon not shared more broadly with HGSOC. Interest-
ingly, OCMs 80–2 and 87 may be clear-cell-derived [30], 
and while OCM.80–2 is PARGi sensitive and has reduced 
DNA replication transcripts, OCM.87 is more resistant 
and does not, reinforcing the need to analyse PARGi sen-
sitivity in a broad range of OCMs.
Another complication extending observations from 
established cell lines to OCMs is chromosome instabil-
ity (CIN). Although ovarian cancer cell lines exhibit CIN, 
it is markedly reduced compared with the mitotic chaos 
observed in primary cultures, most probably because 
extended ex vivo propagation selects fitter, relatively sta-
ble clones [13, 59]. Constant chromosome reshuffling 
likely generates transcript heterogeneity, in turn influenc-
ing drug sensitivity and the stability of gene expression 
signatures [60–62]. Interestingly, the two PARGi-sen-
sitive OCMs that displayed PARGi-induced replication 
stress (109 and 246) have karyotypes dominated by rela-
tively stable monosomies and disomies, compared with 
the highly variable chromosome gains and focal ampli-
fications typical of resistant OCMs (Fig. S5F). Exploring 
the relationship between karyotypic features, CIN and 
PARGi sensitivity will also be facilitated by a broad range 
of well-characterised OCMs.
And finally, the correlation between replisome gene 
expression and PARGi sensitivity is partly a circular argu-
ment. Our initial focus on replisome genes was moti-
vated by (a) the replication catastrophe phenotype, and 
(b) the emergence of replisome genes in a PARGi-sensi-
tiser RNAi screen [26]. In turn, interrogating replisome 
genes led us to test sensitivity of OVMANA, OVISE and 
RMG1, which we now confirm have relatively low expres-
sion levels of DNA replication genes. This highlights the 
need to take fresh, unbiased approaches on larger collec-
tions of OCMs with defined drug sensitivity. Indeed, it is 
striking that the expression of S-phase and mitotic genes 
correlates strongly, not only in the panel of 10 established 
cell lines but generally across the CCLE dataset and our 
cohort of OCMs. This raises the possibility that the dif-
ferential gene expression between PARGi-sensitive and 
-resistant cell lines is mediated by a common upstream 
regulatory network, e.g. the E2F network, which drives 
both S-phase and mitotic gene expression programs [63]. 
Indeed, E2F network genes, along with DNA replication 
and mitotic spindle genes, are up-regulated following 
introduction of TP53 and BRCA1 mutations in a cell line 
model of ovarian cancer development, corresponding 
with the emergence of CIN [64]. Alternatively, correlated 
expression of S-phase and mitotic genes may inde-
pendently arise in response to the same selective pres-
sure, namely oncogene-induced replication stress. The 
stronger correlation observed for our cell line panel, than 
in cancer cell lines generally, in a disease characterised by 
high levels of CNV, implies that a common evolutionary 
pressure is a more likely explanation. Interestingly, in the 
yeast model alluded to above, in addition to DNA replica-
tion processes, sister chromatid cohesion networks were 
also repeatedly altered by exposure to replication stress 
[55]. PARGi-sensitivity may therefore reflect a broader 
adaptation of cell cycle processes that arise in response 
to oncogene-induced deregulation of cell cycle controls.
Synthesising these issues, we conclude that the rela-
tionship between the expression levels of replisome genes 
and PARGi sensitivity is more complex than initially 
proposed [26]. Therefore, developing robust predictive 
biomarkers with potential for clinical utility will require 
more mechanistic insight, driven by both hypothesis-
led and unbiased approaches. Nevertheless, a key out-
come of this study is the identification of two OCMs that 
are particularly sensitive to single-agent PARG inhibi-
tion. While we previously described OCMs sensitive 
to PARGi in combination with a CHK1 inhibitor [26], 
these latter observations indicate that PARG inhibitors 
may have efficacy as monotherapies. This is encouraging 
because there is a need for new therapeutic agents, with 
appropriate predictive biomarkers, and in particular for 
the large cohort of women with HRP HGSOC who are 
unlikely to benefit from PARP inhibitors. A key question 
therefore is whether PARG inhibitors will offer distinct 
therapeutic opportunities to PARP inhibitors. Interest-
ingly, our screen identified a similar proportion of OCMs 
with PARGi and PARPi sensitivity, and of seven PARGi-
sensitive OCMs, four were PARPi-resistant, consistent 
with previous reports that PARGi and PARPi sensitiv-
ity are mostly non-overlapping [26, 28]. Indeed, of the 
six PARGi-resistant established cell lines used in this 
study, four are sensitive to Olaparib, and of four PARGi-
sensitive cell lines, only two are sensitive to Olaparib. 
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Non-overlapping sensitivity to PARPi and PARGi may 
seem counter-intuitive, as PARP1/2 and PARG work in 
concert to repair DNA damage; one might expect that 
both PARPi and PARGi would be toxic towards tumour 
cells with defects in DNA damage repair [22]. However, 
while some studies suggest synthetic lethality between 
BRCA1/2 mutations and PARG inhibition [22, 24] oth-
ers do not [26, 65]. Indeed, two of the PARGi-resistant 
cell lines, COV362 and OVSAHO, have reported BRCA 
defects [45, 66, 67] and are PARPi-sensitive. Moreover, in 
terms of PARGi-sensitive lines, OVMANA, Kuramochi, 
RMG1 and OCM.109 have BRCA1/2 mutations or dele-
tions, while OVISE is BRCA1/2 wildtype and OCM.246 
has a BRCA2 reversion. Thus, our analysis confirms that 
BRCA and HR status do not predict PARGi sensitivity, 
highlighting the need for more mechanistic insight to 
drive biomarker development.
Conclusions
Here we show that in a panel of established cell lines, 
PARGi sensitivity is accompanied by hallmarks of rep-
lication catastrophe, and correlates with lower expres-
sion of DNA replication genes. We also identify several 
patient-derived OCMs that are sensitive to PARGi mono-
therapy, again via a DNA replication catastrophe mecha-
nism. However, DNA replication gene expression did not 
correlate with sensitivity of the OCMs meaning a DNA 
‘replication stress’ gene expression signature is unlikely 
to be a sufficient predictive biomarker for PARG inhibi-
tor sensitivity in a clinical cohort of HGSOC. These 
results highlight the complexity of developing a predic-
tive biomarker for PARGi sensitivity. Thus, while further 
research is required to delineate mechanisms of PARGi 
sensitivity and to develop predictive biomarkers, this 
study nonetheless reinforces the potential of PARG as a 
new therapeutic target for women with HGSOC, includ-
ing those who develop platinum-resistant disease who 
currently have an overall survival of only ~ 12 months 
[68]. Significantly, OCMs 109 and 246, the two most 
highly PARGi-sensitive, were biopsied from women 
with platinum-resistant disease. Moreover, although 
patient 246 was previously treated with Olaparib main-
tenance monotherapy, OCM.246 has a BRCA2-reversion, 
is HRP and PARPi-resistant. Thus, this study indicates 
that PARG inhibitors may represent a future alternative 
treatment for patients with otherwise limited therapeutic 
options, such as those with disease that is platinum and/
or PARPi resistant, and informs the design of early clini-
cal studies of PARG inhibitors.
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Additional file 1: Fig. S1. Ovarian cancer cell lines exhibit differential 
sensitivity to PARGi and PARPi. (A) Colony formation in the continuous 
presence of 1 μM PARGi, 1 μM PARPi or DMSO (Control). Representative of 
≥3 biological replicates. (B) Quantification of colony area with constant 
PARGi treatment or (C) 24–72 h wash‑out PARGi treatment, normalised to 
DMSO‑treated cells (Control) and represented as fold‑change. Mean of ≥3 
biological replicates. Samples below dotted line have > 80% reduction in 
colony formation. (D) Exemplar PARGi‑resistant (OVSAHO) and PARGi‑
sensitive (OVMANA) cell proliferation curves (measured as green object 
count, GOC), at increasing concentrations of PARGi. Mean of 2 biological 
replicates. (E) AUC from (D) were used to dose‑response curves shown. 
Mean of 2 biological replicates. (F) Proliferative  EC50 values for the cell 
line panel. Mean of ≥2 biological replicates. PRISM could not accurately 
calculate  EC50 for resistant cells, therefore for highly resistant cell lines 
 EC50 was approximated as 50 μM (half the maximal concentration tested), 
and for less highly resistant OV56,  EC50 was determined manually. (G) 
Quantification of colony area in response to continuous PARPi treatment 
quantified normalised to DMSO‑treated cells (Control) and represented as 
fold‑change. Samples below dotted line have > 80% reduction in colony 
formation. Mean of ≥3 biological replicates. Statistics: 2‑way ANOVA with 
Dunnett’s multiple comparisons test, selected comparisons were between 
drug treatments and DMSO control within each cell line. Error bars repre‑
sent SEM. (H) Venn diagram summarising differential sensitivity. *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001.
Additional file 2: Fig. S2. PARGi stabilises PAR chains in cell lines irre‑
spective of PARGi sensitivity. (A) Quantification of PAR staining intensity 
in response to 48 h treatment with DMSO (Control), 1 μM PARGi, and 
co‑treatment with 1 μM PARGi and 1 μM PARPi using single‑cell immu‑
nofluorescence microscopy in 1 biological replicate (dot plots, 1000 cells 
shown per condition). (B) Representative immunofluorescence images 
of PAR staining from (A), in PARGi‑resistant (COV318) and PARGi‑sensitive 
(OVMANA) cell lines. Scale bar: 20 μm. (C) Quantification of PAR staining in 
response to PARGi or co‑treatment with PARGi and PARPi, normalised to 
DMSO‑treated cells (Control). Mean of ≥3 biological replicates. (D) Repre‑
sentative immunoblot showing PAR chain formation in response to 48 h 
treatment with DMSO (Control), or 1 μM PARGi. (E) PAR immunoblot in (D), 
without adjustment to show inter‑line variation. (F) Mean quantification 
of PAR staining by immunoblotting (≥2 biological replicates). Statistics: 
2‑way ANOVA with Dunnett’s multiple comparisons test, selected com‑
parisons were between drug treatments and DMSO control. Error bars 
represent SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Additional file 3: Fig. S3. PARGi sensitivity is accompanied by markers 
of replication stress and the DNA damage response. (A) Quantification of 
foci per nucleus after 48 h of 1 μM PARGi treatment (γH2AX and RPA1), or 
nuclear pKAP1 intensity after 72 h of 1 μM PARGi treatment using single‑
cell immunofluorescence microscopy in 1 biological replicate (dot plots, 
1000 cells shown per condition). (B) Upper panel: Quantification of foci per 
nucleus after 48 h of 1 μM PARGi treatment (γH2AX and RPA1), or nuclear 
pKAP1 intensity after 72 h of 1 μM PARGi treatment; Lower panel: Results 
from upper panel normalised to DMSO‑treated cells (Control) and repre‑
sented as fold‑change. Mean of ≥3 biological replicates. (C) Representa‑
tive immunoblot for Chk1 and pChk1, following 48 h with 1 μM PARGi (Gi) 
or DMSO as a negative control (C), or for 2 h with 2 mM hydroxyurea (H) 
as a positive control. Tao1 serves as loading control. (D) Quantification of 
Li‑COR pChk1 immunoblotting shown in Fig. 2C, mean of ≥3 biological 
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replicates. Data are expressed as the increase resulting from treatment 
as a percentage of maximum response (achieved with hydroxyurea [H]) 
to correct for inter‑line variation i.e. % PARGi (pChk1/Chk1)/H ‑ % DMSO 
(pChk1/Chk1)/H. Statistics: 2‑way ANOVA with Sidak multiple comparisons 
test (B, D), selected comparisons were between PARGi treated values and 
DMSO control within each cell line. Error bars represent SD (A), SEM (B, D). 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Additional file 4: Fig. S4. Comparison of NanoString with CCLE and Klijn 
datasets; DNA replication and mitotic gene expression correlation. (A) Box 
and whisker plots for DNA replication (red), mitotic (blue) and apoptotic 
(grey) gene Z scores in 10 cell line panel. Values on left side indicate Pear‑
son  R2 for CCLE or data from Klijn et al., compared with the NanoString 
analysis. (B) XY plot of the correlation between DNA replication and 
mitotic (red), and DNA replication and apoptotic (grey) gene expression. 
Z scores sums for epithelial cancer cell lines in Broad 2019 CCLE dataset 
[39]. Ten cell line panel indicated by black diamonds, note OV56 CCLE 
expression data does not reflect NanoString expression data (see text). 
Pearson  R2 values indicated below the graph, all comparisons, p < 0.0001, 
total number cell lines 747. ns = not significant, *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001.
Additional file 5: Fig. S5. Validation of patient‑derived OCMs as bona fide 
models of HGSOC. (A) Representative images of severely atypical nuclei 
seen across OCMs. Scale bar: 10 μm. (B) Representative images of CK7 
and PAX8, and p53 mutation‑type (OCM.106: absent nuclear expression; 
OCM.195: strong/diffuse nuclear expression, involving > 80% tumour cell 
nuclei) by immunofluorescence staining. Scale bar: 20 μm. (C) Representa‑
tive images of CK7, PAX and p53 mutation‑type (OCM.92: absent nuclear 
expression; OCM.191: strong/diffuse nuclear expression, involving > 80% 
tumour cell nuclei) by immunohistochemistry staining from archival 
tumour blocks. Scale bar: 500 μm (× 10 magnification) and 100 μm (× 40 
magnification). (D) Representative p53 immunoblot e.g. showing absent 
(OCM.86) and strong p53 bands (OCM.105). The control well represents 
stromal cells from the patient sample associated with OCM.237. Tao1 
serves as loading control. (E) Representative somatic TP53 variants 
detected in OCMs. (F) Exemplar images of genome‑wide chromosome 
copy‑number profiles determined by single‑cell whole‑genome sequenc‑
ing showing aneuploidies and rearranged chromosomes in tumour cells. 
Each row represents a single cell, with chromosomes plotted as columns 
and colours depicting copy‑number state. See also Supplementary 
Table 1.
Additional file 6: Fig. S6. Living biobank screen demonstrated broad 
range of PARGi and PARPi sensitivity. (A) Colony formation following 
96 h of treatment with 1 μM PARGi or 1 μM PARPi or DMSO (Control). 
(B) Quantification of ca from (A) following 1 μM PARGi (B) or 1 μM PARPi 
(C), normalised to DMSO‑treated cells (Control) and represented as 
fold‑change. BRCA status (germline, or, where available, OCM) indicated 
as follows: + = BRCA status of OCM; W=BRCA1/2 wild‑type; B=BRCA1/2 
mutation; V=BRCA1/2 variant of uncertain clinical significance; R = puta‑
tive BRCA1/2 reversion; ▼=prior PARPi therapy. Single technical replicate. 
(D) Exemplar images of colony formation following continuous treatment 
with 1 μM PARGi or 1 μM PARPi or DMSO (Control). Representative images 
of 3 biological replicates. (E) Quantification of ca from (D) normalised to 
DMSO‑treated cells (Control) and represented as fold‑change. Mean of 3 
biological replicates. Error bars represent SEM. See also Supplementary 
Table 2 and Fig. 5A, B. ***p < 0.001, ****p < 0.0001.
Additional file 7: Fig. S7. On‑target inhibition of PARG in PARGi‑sensitive 
OCMs. (A) Chemical structure of inactive small molecule analog of PARGi, 
PARGi‑Me (PDD00031704). (B) Colony formation of PARGi‑sensitive OCMs 
(109, 191 and 246) following continuous treatment with 1 μM PARGi or 
1 μM PARGi‑Me or DMSO (Control). Representative images of 3 biological 
replicates. (C) Upper panel – Proliferative Log  EC50 values for PARGi and 
PARGi‑ME for PARGi‑sensitive OCMs. Mean of 3 biological replicates. Error 
bars represent SEM. Statistics: Unpaired t‑test of PARGi versus PARGi‑Me. 
Lower panel – Quantification of ca from (B) normalised to DMSO‑treated 
cells (Control) and represented as fold‑change. Mean of 3 biological 
replicates. Statistics: Unpaired t‑test of PARGi versus PARGi‑Me. Error bars 
represent SEM. ***p < 0.001, ****p < 0.0001.
Additional file 8: Fig. S8. PARGi suppresses mitotic entry in sensitive 
OCMs. (A) Cell fate profiling, showing cell behaviour over 120 h treatment 
with 1 μM PARGi or DMSO (Control). Each horizontal line represents a 
single cell, with the colours indicating cell behaviour. Following mitosis, 
one daughter cell was chosen at random to continue the analysis. No 
mitotic entry does not include death in interphase where mitosis does not 
take place. Abnormal mitosis includes cell division, abnormalities such as 
tripolar cell divisions, binuclear daughter cells and division of binuclear 
cells. Slippage is recorded where cells enter mitosis, then exit without 
division. Fusion was recorded where daughter cells appear to separate but 
subsequently join back together. Representative of 2 biological replicates. 
(B) Number of cells that fail to enter mitosis over 120 h (maximum n = 50) 
following 1 μM PARGi, 1 μM PARPi or DMSO (Control). Statistics: 2‑way 
ANOVA with Dunnett’s multiple comparisons test, selected comparisons 
were between PARGi or PARPi treated cells versus DMSO control. Mean 
of 2 biological replicates. Error bars represent SEM. (C) Exemplar image 
of CENPF (indicating  G2 cells) and Rad51 immunofluorescence staining 
of OCM.246 after 2 Gy X‑ray ionising radiation followed by 24 h PARPi, ▼ 
indicates an HRP cell (positive for CENPF with > 5 Rad51 foci). Scale bar: 
10 μm. Bar chart shows fold‑change in % [Rad51 + CENPF+ cells/CENPF+ 
cells] in DMSO‑treated cells versus cells treated with 2 Gy X‑ray ionis‑
ing radiation followed by 24 h 1 μM PARPi. Dotted line indicates a 2‑fold 
change, above which cells are considered HRP (below it HRD).
Additional file 9 Fig. S9. Low expression of mitotic or apoptotic gene 
sets does not identify OCMs sensitive to PARGi. (A) XY plot showing cor‑
relation between sum of Z scores for mitotic and DNA replication genes 
for each OCM (p < 0.0001, Pearson’s  R2 = 0.774). (B) Heatmaps showing 
RNAseq of 29 OCMs ranked by sum of z‑scores for 25 mitotic (left) and 
apoptotic (right) genes where red = high expression; white = average 
expression; and blue = low expression. (C) XY plots showing colony forma‑
tion area and the sum of z‑scores for the expression of 25 mitotic (left) 
and apoptotic (right) genes from RNAseq of 29 OCMs. PARGi sensitivity as 
determined by colony formation assay (see Fig. S6B). Note: RNAseq was 
unavailable for OCMs 267, 250–2, and 162–2.
Additional file 10: Supplementary Table 1. Clinical data, OCMs and 
primary tumour blocks. The table outlines the clinical data for the 25 new 
HGSOC OCMs screened for PARPi and PARGi sensitivity. Key:  dx, diagnosis; 
FIGO, International Federation of Gynecology and Obstetrics; gBRCA m, 
germline BRCA1/2 mutation; VUS, variant of uncertain clinical significance; 
CTx, chemotherapy; Ref, platinum‑refractory disease (tumour progression 
during or within 4 weeks of completing platinum therapy); Res, platinum‑
resistant (tumour progression between 4 weeks and 6 months from 
completing platinum therapy); Sens, platinum‑sensitive (tumour progres‑
sion ≥6 months from completing platinum therapy). CN, chemonaïve; OS, 
overall survival; mo, months; WT, wild‑type; FR, frameshift; NS, nonsense; 
IF, immunofluorescence; IHC, immunohistochemistry; For IF and IHC: 
CK7 and PAX8, coloured box (present), white box (absent), S, strong; P, 
patchy; F, focal; W, weak. p53 is either mutant‑type (strong/diffuse nuclear 
staining; darker coloured box), wild‑type (lighter colour box) or absent 
nuclear staining (white box). NE, not evaluable (antibody failed); block 
unavailable (grey box). IB, immunoblotting; For IB: +(sm), band present 
but at lower than 53 kDa; +(S), strong band present; *At the time of the 
research biopsy; †Histologically re‑classified from HGSOC to intermediate 
grade (grade 2/moderately differentiated) serous adenocarcinoma follow‑
ing tumour block analysis; ‡cell agar block only, histologically re‑classified 
from HGSOC to suspicion of adenocarcinoma arising from the gynaeco‑
logical tract. Clinical data for previously characterised OCMs are published 
[13], and not repeated here. Supplementary Table 2. BRCA1/2 variants 
detected in OCMs. The table outlines the BRCA1/2 variants detected in the 
panel of 7 OCMs screened for PARGi and PARPi sensitivity using colony 
survival and cell proliferation assays. Variants are described using Human 
Genome Variation Society (HGVS) nomenclature. Key: FR, frameshift; 
MS, missense; NS, nonsense; VAF, variant allele frequency; VUS, variant of 
uncertain clinical significance; WT, wild‑type. All OCMs underwent both 
NGS and MLPA testing for BRCA1/2 variants. Supplementary Table 3.  EC50 
values for OCMs for the inhibitors/compounds tested. The table outlines 
the  EC50 values for the inhibitors/compounds tested in the cell prolifera‑
tion assay for the panel of 7 OCMs assessed. See Fig. 5C and D for Log  EC50 
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values. Data are mean ± SEM from 3 biological replicates. PRISM could not 
accurately calculate  EC50 for PARGi‑resistant cells, therefore for resistant 
OCMs, the  EC50 was approximated as 50 μM (half the maximal concentra‑
tion tested) and described in the table as not calculable (NC).
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